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Menorrhagia significantly impairs the quality of life of many women and causes major health care
costs. Hysterectomy has been the standard treatment for menorrhagia, with a high satisfaction rate.
However, alternative management strategies have gained in popularity and raised questions about the
cost, morbidity, health-related quality of life (HRQoL) and possible long-term effects on health
associated with treatment modalities. Levonorgestrel-releasing intrauterine system (LNG-IUS) has
been advocated as an alternative to surgery.
The VuoKKo trial set out to assess and compare the LNG-IUS and hysterectomy in the treatment of
menorrhagia, and it consisted of 236 women, aged 35–49 years, referred for menorrhagia to the five
university hospitals in Finland between November 1994 and November 1997. Of these women, 117
were randomized to treatment with hysterectomy and 119 to treatment with LNG-IUS. The follow-up
visits took place at 6 months and 1 year after treatment and again 5 and 10 years after randomization.
The objective of this present study was to identify and compare the cost-effectiveness and effects on
HRQoL, pain, lower urinary tract symptoms (LUTS) and cardiovascular disease (CVD) risk factors of
these two treatment modalities during a 10-year follow-up. The continuation rate at 10 years was 94%.
Of the 119 women assigned to LNG-IUS, 55 (46%) subsequently underwent hysterectomy over the 10
year period. Of the women assigned to hysterectomy, 109 (93%) underwent hysterectomy. The
analyses for HRQoL, cost-effectiveness and pain were performed by intention-to-treat principle and
for lower urinary tract symptoms and cardiovascular disease risk factors by actual treatment principle.
HRQoL and other measures of psychosocial well-being (anxiety, depression, sexual function)
improved during the first 5 years, but diminished between 5 and 10 years, and the improved HRQoL
returned to almost its baseline levels, presumably due to ageing. No significant differences emerged
between the LNG-IUS and hysterectomy groups, but the overall costs per participant were
substantially lower in the LNG-IUS group ($3423) than in the hysterectomy group ($4937).
Both hysterectomy and LNG-IUS decreased pain. At baseline, 45% of the women in the LNG-IUS
group and 38% of the women in the hysterectomy group reported lower abdominal pain, and 64% /
65% of the women reported back pain. At 10 years, 16% (LNG-IUS) and 18% (hysterectomy) of the
women reported lower abdominal pain and 38% / 36% reported back pain. In both groups, the pain
decreased most during the first 6 months and monthly frequent pain decreased most of all. Lower
abdominal pain score (occurrence and intensity combined) decreased in both groups during the 10
years, but back pain score decreased only in the LNG-IUS group.
9Women treated by hysterectomy used more often medication for urinary incontinence than women
treated by LNG-IUS (12% vs. 1%, p=0.006) during the 10-year follow-up. Moreover, urinary tract
infections (34% vs. 14%, p=0.002), feeling of incomplete emptying (19% vs. 9%, p=0.04) and stress
urinary incontinence (48% vs. 34%, p=0.04) were more common in women with hysterectomy than in
LNG-IUS users.
The CVD risk profile showed that women treated by hysterectomy had higher levels of inflammatory
cytocines, tumour necrosis factor ? at 5 years (median 108.59 vs. 49.02 pg/ml, p=0.001) and high-
sensitivity C-reactive protein at 10 years (median 1.55 vs. 0.78 mg/ml, p=0.04) than women treated by
LNG-IUS. No differences between the groups were detected in traditional cardiovascular disease risk
factors. Women treated by hysterectomy used more often oestrogen therapy than women treated by
LNG-IUS at 5 years (29% vs. 10%, p=0.003) and 10 years (56% vs. 27%, p<0.001) after the
treatment.
In conclusion, LNG-IUS is a safe and cost-effective alternative to hysterectomy in the treatment of
menorrhagia. Despite 46% of women assigned to LNG-IUS eventually having a hysterectomy, the
overall costs were approximately 31% lower in the LNG-IUS group than in the hysterectomy group.
Both hysterectomy and LNG-IUS have a favourable effect on HRQoL and pain in menorrhagia
patients, but hysterectomy seems to predispose women more to CVD risk factors and LUTS over the
long run.
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1. Introduction
Heavy cyclical menstrual bleeding over several consecutive cycles is known as menorrhagia.
Menorrhagia is a common health problem, affecting nearly one-third of women at some point during
their reproductive years and causing distress and ill health in women worldwide (Rees 1987, Shapley
et al. 2004).
Hysterectomy has been a preferred treatment option for menorrhagia due to its immediate
effectiveness and definitiveness. However, the morbidity and costs associated with hysterectomy
cannot be ignored (Fernandez et al. 2003, Hurskainen et al. 2004b). Less invasive treatment options,
such as levonorgestrel-releasing intrauterine system (LNG-IUS) and endometrial ablation (EA), are
becoming increasingly popular. Of the medical treatment modalities, LNG-IUS is well tolerated and
the most effective (Marjoribanks et al. 2006). Both hysterectomy and LNG-IUS have high satisfaction
rates among menorrhagia patients (Hurskainen et al. 2004b). Randomized studies comparing LNG-
IUS and hysterectomy in the treatment of menorrhagia are few (Matteson et al. 2012). The Finnish
VuoKKo study carried out in 1994 aimed to compare health-related quality of life (HRQoL) and costs
after hysterectomy and LNG-IUS. After 1 and 5 years, both treatments had a similar favourable effect
on HRQoL, but the costs associated with treatment were substantially lower in the LNG-IUS group,
despite many (20% at 1 year and 42% at 5 years) of the women assigned to this group eventually
having to undergone hysterectomy (Hurskainen et al. 2004b). This study was conducted to determine
whether  the  impact  of  the  two  treatments  on  HRQoL  and  costs  remains  after  10  years,  when  the
women have aged and most have reached menopause. Moreover, the long-term effect of these
treatment options on other aspects of health needed to be elucidated.
Dysmenorrhoea, lower abdominal pain and back pain are common among menorrhagia patients
(Molnar et al. 1997, Hurskainen et al. 2001a). Hysterectomy is an efficient treatment for
dysmenorrhoea, and in most women chronic pelvic pain decreases after hysterectomy (Learman et al.
2004). Previous studies have shown that also LNG-IUS decreases dysmenorrhoea and chronic pelvic
pain (Bahamondes et al. 2007, Anpalagan and Condous 2008, Alhamdan et al. 2010). However, no
comparative studies of the impact of these treatments on abdominal pain or back pain in menorrhagia
patients exist.
Female urinary incontinence (UI) is an increasingly common complaint (Miner 2004, Kenton et al.
2006). Hysterectomy has been linked to lower urinary tract symptoms (LUTS), including UI, in some,
but not all, studies (Brown et al. 2000, van der Vaart et al. 2002, Altman et al. 2007). The long-term
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effect of hysterectomy on LUTS has not been investigated extensively and studies evaluating the
impact of hysterectomy on urinary tract infections are lacking.
Cardiovascular diseases (CVDs) are the main cause of death in Western countries. Hysterectomy
impairs ovarian function and may cause early menopause (Halmesmäki et al. 2004, Farquhar and
Steiner 2005, Moorman et al. 2011). Early menopause, in turn, increases the risk for CVDs (Punnonen
et al. 1987, Kharazmi et al. 2007). LNG-IUS seems to have a marginal effect on ovarian function and
no effect on menopausal age (Barbosa et al. 1990, Halmesmäki et al. 2004, Halmesmäki et al. 2007a).
Consequently, the aim of this study was to evaluate and compare the effects of LNG-IUS and
hysterectomy on HRQoL, pain, LUTS and CVD risk factors in the treatment of menorrhagia and the
long-term costs of these two treatment options.
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2. Review of the literature
2.1 Menorrhagia
Menorrhagia is subjectively defined as a complaint of heavy cyclical menstrual bleeding occurring
over several consecutive cycles (Royal College of Obstetricans and Gynaecologists 1998).
Objectively, menorrhagia is a total menstrual blood loss (MBL) of 80ml or more per menstruation
(Hallberg and Nilsson 1964).  This threshold is derived from population studies showing that average
MBL is between 30 and 40 ml, and that 90% of women have blood losses of less than 80ml (Hallberg
et al. 1966a, Cole et al. 1971). Moreover, MBL of over 80 ml has been found to be associated with
iron deficiency anaemia (Hallberg et al. 1966b). However, half of the women with a subjective
complaint of menorrhagia have been shown to have normal levels of MBL when MBL is actually
measured (Fraser et al. 1984, Higham et al. 1990, Hurskainen et al. 1998). Thus, factors other than the
actual amount of MBL are likely to affect the threshold for seeking care. Perception of menorrhagia is
subjective and management usually depends upon what symptoms are acceptable to an individual. In
this study, menorrhagia is defined as a complaint of heavy regular menstrual bleeding over several
consecutive cycles.
Menorrhagia may be the result of systemic or uterine disorder or iatrogenic causes (Rees 1987,
Livingstone and Fraser 2002). Systemic disorders include hypothyroidism and haematological
disorders such as bleeding diatheses, e.g. von Willebrand’s disease (Krassas et al. 1999). Local
disorders include adenomyosis, fibroids and endometrial polyps (Livingstone and Fraser 2002).
Iatrogenic disorders result from medications such as anticoagulant therapy or copper intrauterine
device. In half of all cases, no specific aetiology is known and menorrhagia is called essential.
Nevertheless, a strong association has been described between family history and essential
menorrhagia (Kuzmina et al. 2011). In this study menorrhagia refers to essential menorrhagia.
The pathogenesis of essential menorrhagia is poorly understood. Approximately 50% of menorrhagia
patients present no evidence of uterine pathology at hysterectomy (Clarke et al. 1995), suggesting a
defect in the cellular process and regulatory mechanism of menstruation. In ovulatory cycles,
excessive MBL has been ascribed to abnormal uterine levels of prostaglandins (Hagenfeldt 1987,
Livingstone and Fraser 2002). Moreover, endometrial fibrinolytic enzymes and increased fibrinolysis
appear to have an important role in menorrhagia (Gleenson 1994). In addition, disturbed angiogenesis
and abnormal vascular smooth muscle cells of endometrial spiral arterioles in women with
menorrhagia have been associated with an enhanced role of vascular endothelial growth factor and
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with a delay in differentiation and maturation of the vessel wall (Kooy et al. 1996, Smith 1998, Mints
et al. 2007).
Assessing MBL is the main problem in the diagnosis of menorrhagia, and several methods to
determine the amount of MBL have been developed. MBL can be measured by alkaline haematin
extraction method, which is the most accurate measure of MBL, but requires collection of sanitary
pads and is difficult in everyday practice (Hallberg and Nilsson 1964, Hurskainen et al. 1998). Total
menstrual  fluid loss  can also be used as  an assessment  of  MBL. Measurement  is  determined by the
difference in weight of tampons or pads before and after use (Reid and Virtanen-Kari 2005). This
method does not give accurate information of blood volume because women secrete different amounts
of exudates from the uterus and vagina. Haemoglobin concentration measure is widely used in
assessment of MBL. When MBL exceeds 80 mL, the incidence of anaemia (haemoglobin less than
120 mg/L) is increased significantly (Hallberg et al. 1966b, Janssen et al. 1995). However, the
association is very inaccurate because the amount of iron in food and normal haemoglobin levels in
individuals varies.
A simpler measure that is often used is the pictorial blood loss assessment chart (PBAC), by which the
amount of MBL is determined visually using a pictorial chart form (Higham et al. 1990, Janssen et al.
1995, Reid et al. 2000). The Finnish Current Care guideline for menorrhagia treatment recommends
use of interviews and survey forms for menorrhagia patients to facilitate diagnosis-making and to
assess the impact on HRQoL and the amount of MBL (Current Care editorial office 2005, updated
2009). The forms contain a PBAC and a score of over 185 points indicates 75-86% probability for
objective menorrhagia. Nevertheless, history and the effect of menorrhagia on the woman’s life are the
most important information in the diagnosis, and in practice the treatment of menorrhagia is based on
these.
Epidemiology and impact on life
Menorrhagia is an important health care problem. An estimated 25 - 30% of women complain of
menorrhagia during their reproductive years (Rees 1987, Garry et al. 2004, Shapley et al. 2004).
Menorrhagia is one of the most predominant complaints in women referred to gynaecologists
accounting for 10 – 20 % of outpatient referrals to gynecology (Coulter et al. 1989, Lethaby et al.
2005). In the UK, 5% of women aged 30-49 years consult their general practitioners each year for
menorrhagia (Duckitt and Collins 2007), and according to a Finnish population survey 5% of women
aged 25-55 years (50 000 women) annually feel the need for examination or treatment for menorrhagia
(Luoto et al. 2004). However, some cultural influences have been found to determine whether or not a
woman will seek medical care for menorrhagia, including her status in the society (Kuh and Stirling
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1995). Subjective menorrhagia and likelyhood to complain of menorrhagia seem to correlate with
lower socioeconomic status, unemployment, abdominal pain, and psychological distress (Kuh and
Stirling 1995, Hurskainen et al. 2001a, Shapley et al. 2004). Menorrhagia markedly interferes with
daily activities and impairs the quality of life (QoL) of affected women (Coulter et al. 1994,
Hurskainen et al. 2001b, NICE 2007, Frick et al. 2009). Moreover, menorrhagia is the most common
cause of iron deficiency anaemia among fertile-aged women and causes substantial work loss (Cote et
al. 2002, Liu et al. 2007). Menorrhagia creates a major burden in terms of financial costs for women
and health care resources for society (Liu et al. 2007, Frick et al. 2009).
2.2 Treatment of menorrhagia
Essential menorrhagia can be treated medically or surgically. Medical treatments include oral
medication and LNG-IUS (Table 1). Surgical options include mini-invasive surgery (EA) and
hysterectomy (Table 1). The choice of treatment depends on personal choice of the woman, desire for
future pregnancy and general health status (Vuorma et al. 2003, Wheeler et al. 2012). In addition,
safety, efficacy, cost and availability of different treatment modalities affect which treatment is chosen
(Marjoribanks et al. 2006, Wheeler et al. 2012). Guidelines for treatment of menorrhagia were
released in Finland in 2005 (Current Care editorial office 2005, updated 2009), and two years later in
the UK (NICE 2007). Medical treatment is usually preferred as first-line treatment of menorrhagia by
women and professionals (Marjoribanks et al. 2006, Current Care guideline 2005, updated 2009,
NICE 2007, Nelson 2010).
2.2.1 Levonorgestrel-releasing intrauterine system (LNG-IUS)
Of the medical treatment options, LNG-IUS (Mirena®, Bayer Oy, Turku, Finland) is the most
effective in reducing MBL (Marjoribanks et al. 2006, Fraser 2010, Kaunitz and Inki 2012). It has been
reported to reduce MBL by 80-97% after three months and to be well accepted by most women (Irvine
et al. 1998, Luukkainen 2000). Amenorrhea occurs in 50–75% women with menorrhagia following
LNG-IUS insertion (Stewart et al. 2001, Varma et al. 2006). The reduction in bleeding associated with
LNG-IUS use has been associated with a significant increase in haemoglobin level (Luukkainen 2000,
Kriplani et al. 2007).
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LNG-IUS was initially developed for contraception during the 1970s-1980s; it was licensed for
contraceptive use in Finland in 1990 (Nilsson et al. 1981a, Luukkainen et al. 1990). The usefulness
and effectiveness of LNG-IUS for menorrhagia were soon noted and LNG-IUS was licensed for
treatment of menorrhagia in Finland in 1995. Mirena® has been approved by the Food and Drug
Administrations in USA and is licenced in 130 countries worldwide for contraception and in 120
countries for a second indication – treatment of menorrhagia (according to information provided by
Bayer Oy, 2012). Over 12 million women worldwide use LNG-IUS, but it is impossible to determine
how many of them use it for contraception and how many for menorrhagia treatment or hormone
replacement therapy.
Structure of LNG-IUS
LNG-IUS consists of a 32-mm-long T-shaped polyethylene frame with a hormone reservoir
containing 52 mg of levonorgestrel on the stem (Figure 1). Levonorgestrel is the biologically active
form of norgestrel (d-norgestrel) and is a synthetic second-generation progestin. The LNG-IUS is
approved for up to 5 years’ use. However, there is evidence of effectiveness beyond this period
(Faundes et al. 1993, Seeber et al. 2012). Initially, 20 ?g of levonorgestrel / 24 hours is released into
the uterine cavity, declining progressively to 11 ?g after 5 years of use (Luukkainen et al. 1990). The
concentration of levonorgestrel in the endometrium achieved with LNG-IUS is higher than with much
greater daily oral doses of levonorgestrel. The mean systemic plasma level of levonorgestrel with
LNG-IUS is less than those achieved with therapeutic oral or parental doses of progestogens and it
decreases over time (191±71 pg/ml (mean±SD) in the first year of use, 157±68 pg/ml in the second
year of use, 134±41 pg/ml in the third year of use and 133±48 pg/ml in the seventh year of use)
(Seeber et al. 2012). Up to 85% of the LNG-IUS cycles are ovulatory (Nilsson et al. 1984,
Lähteenmäki et al. 2000).
Figure 1. Levonorgestrel-releasing intrauterine system (Mirena®). Printed with permission of Bayer Oy.
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Mechanism of action
The mechanism of action of LNG-IUS on menorrhagia is based on a strong local suppressive action of
intrauterine-released levonorgestrel on the endometrium (Silverberg et al. 1986). The endometrium
becomes unresponsive to the proliferative effect of ovarian oestrogen (Nilsson et al. 1984, Barbosa et
al. 1990). The suppression of the endometrium is associated with a marked reduction in the number of
days of bleeding and a reduction of MBL (Pakarinen and Luukkainen 2007). The strong suppression
of the endometrium with glandular atrophy, decidualization of the stroma and inactivation of
endometrial cells occur in the endometrial epithelium within three months after insertion of the LNG-
IUS and remain unchanged during use of LNG-IUS (Silverberg et al. 1986).
Other health benefits
Besides contraception and reduction of MBL, LNG-IUS has many other beneficial health effects with
important public health implications (Lähteenmäki et al. 2000, Pakarinen et al. 2001, Varma et al.
2006, Fraser 2010, Heikinheimo and Gemzell-Danielsson 2012). LNG-IUS is licensed for intrauterine
protection from endometrial hyperplasia or malignant transformation during exogenous oestrogen
therapy in perimenopausal and postmenopausal women in 112 countries (according to information
provided by Bayer Oy, 2012). In addition, LNG-IUS seems to be an effective treatment for fibroid-
related menorrhagia, with a 84-90% decrease of MBL (Soysal and Soysal 2005, Varma et al. 2006).
However, information on whether LNG-IUS is associated with decreased fibroid size or no change in
fibroid size is inconsistent (Maruo et al. 2003, Varma et al. 2006, Heikinheimo and Gemzell-
Danielsson 2012). Several studies have shown a reduction in adenomyosis- and endometriosis-related
dysmenorrhoea, menorrhagia and chronic pelvic pain (Varma et al. 2006, Heikinheimo and Gemzell-
Danielsson 2012). Furthermore, LNG-IUS might decrease premenstrual symptoms (Leminen et al.
2011).
Adverse effects
The most frequent adverse effect (around 10-15% of users) is unscheduled erratic menstrual spotting,
which usually occurs during the first 3-4 months following LNG-IUS insertion, but thereafter tends to
subside (Irvine et al. 1998, Luukkainen et al. 2001). Irregular bleeding is the most common adverse
effect leading to discontinuation of LNG-IUS treatment. Some women experience hormonal side
effects, pain and mood changes (Istre and Trolle 2001, Lethaby et al. 2005). An increased incidence of
ovarian cysts (10%-20% of users) is reported in women using LNG-IUS (Brache et al. 2002, Inki et al.
2002). The cysts are usually transient and resolve spontaneously (Brache et al. 2002, Inki et al. 2002).
In  the  long  term,  the  effect  of  the  LNG-IUS  on  the  risk  of  breast  cancer  (Backman  et  al.  2005,
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Lyytinen et al. 2010) and other cancers remains still largely unclear. Uterine perforation is a rare
complication, but expulsion rates seem to be higher among menorrhagia patients than in the general
population of LNG-IUS users (Kaunitz et al. 2012). Contraindications for LNG-IUS use are uterine
anomaly, active liver disorder and active thromboembolic disease (www.who.int/reproductivehealth).
Table 1. Medical and surgical treatments for essential menorrhagia.
Treatment Mechanism
Reduction in menstrual
bleeding
Contra-
ceptive? Potential unwanted outcomes
Combined oral contraceptives Prevents proliferation up to 50% Yes Mood changes, headaches, nausea,
(COCs)* of the endometrium fluid retention, breast tenderness,
deep vein thrombosis and stroke (rare)
Oral progestins Prevents proliferation Weight gain, bloating,
(days 15-26)** of the endometrium 12-20% No breast tenderness, headaches,
(days 5-26)** up to 87% Yes acne and mood changes
Injected / depot progestins Prevents proliferation Amenorrhea or Yes Weight gain, irregular bleeding,
*** of the endometrium irregular bleeding premenstrual-like syndrome,
loss of bone mineral density
Levonorgestrel-releasing
intrauterine system
Prevents proliferation
of the endometrium
70-95%
(full benefit may not be Yes
Irregular bleeding that may last for over
6 months, hormone-related problems
(LNG-IUS)*,*** seen for 6 months) such as breast tenderness, acne
or headaches and ovarian cysts
(generally transient), uterine perforation
at time of insertion (rare)
Tranexamic acid Antifibrinolytic effect 40-60% No Indigestion, diarrhoea and headaches
*
Non-steroidal anti-
inflammatory drugs
Reduces production
of prostaglandins 33-55% No
Indigestion, diarrhoea, worsening of
asthma in sensitive individuals,
(NSAIDs)*, *** in the endometrium peptic ulcers
Gonadotrophin-releasing
hormone analogue*
Stops production of
oestrogen and
Amenorrhoea in 89%
of women No
Menopause-like symptoms (such as hot
flashes, increased sweating,
(GnRHa)* progesterone vaginal dryness), osteoporosis
Endometrial ablation Destruction of the 70-95% No Vaginal discharge, increased period
(EA)***, **** endometrium by Amenorrhoea 13-64% pain or cramping (even if no further
First generation
(with hysteroscopy)
loop or rollerball with
hysteroscopy or
bleeding), infection, perforation (rare),
need for additional surgery, fluid
Second generation by microwaves or overload during hysteroscopy
with heated fluid without
Hysteroscopy
Hysterectomy Surgical removal of Amenorrhoea Yes Infection, intraoperative haemorrhage,
*** the uterus damage to other abdominal organs,
such as the urinary tract or bowel,
thrombosis (rare), death (very rare),
urinary tract symptoms
*NICE 2007, **Lethaby et al. 2005, ***Marjoribanks el al.  2006, ****Kaunitz et al. 2009
rare = 1 in 10 000 chance, very rare = 1 in 100 000 chance
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2.2.2. Hysterectomy
Hysterectomy is one of the most common surgeries performed on women in the Western world
(Farquhar and Steiner 2002). Of the indications for hysterectomy, fibroids are most common (33-
55%), followed by bleeding disorders (including both menorrhagia and dysfunctional uterine
bleeding) (12-31%) (Vuorma et al. 1998, Mäkinen et al. 2001, Brummer et al. 2009). For
menorrhagia, hysterectomy has been the standard treatment owing to its definitive nature, with
satisfaction rates of over 95% up to three years after surgery (Lethaby et al. 2000b).
In Finland, over 10 000 hysterectomies for benign reasons were performed annually 10 years ago, but
as a result of new treatment guidelines and effective alternatives, the amount has gradually been
decreasing, being around 6000 from the year 2007 awards (5873 in 2009 and 6232 in 2010) (Figure 2)
(Hospital  Discharge  Register  of  the  National  Institute  for  Health  and  Welfare  in  Finland).  In  the
United Kindom the number of hysterectomies performed for menorrhagia declined by 64% between
1995 and 2002 since the introduction of LNG-IUS in 1993 and increased use of EA (Reid 2005).
Figure 2 shows hysterectomies performed for benign indications and for dysfunctional uterine
bleeding (including menorrhagia) as first indication in Finland between 1998 and 2010. Hysterectomy
rates are based on the International Classification of Diseases (ICD-10) codes related to dysfunctional
uterine bleeding (N92). However, the number of hysterectomies for menorrhagia is difficult to
determine as the same women can have a diagnosis of both fibroids and menorrhagia.
The national prospective FINHYST study in 1996 showed abdominal hysterectomy as being most
common (58%) (Mäkinen et al. 2001). Minimally invasive methods have since prevailed over
abdominal hysterectomy, and in FINHYST study in 2006 the national distribution of hysterectomies
by approach was 24% for abdominal hysterectomy, 32% for laparoscopic hysterectomy and 44% for
vaginal hysterectomy (Brummer et al. 2009).
Other health benefits
Hysterectomy is an effective treatment for dysmenorrhea, chronic pelvic pain and lower abdominal
pain related to endometriosis and adenomyosis (Learman et al. 2004, Luciano and Luciano 2011).
Hysterectomy may also decrease the risk of ovarian carcinoma (Chiaffarino et al. 2005) and removes
the risk for uterine pathology. Moreover, perimenopausal and postmenopausal women with
hysterectomy are able to use oestrogen therapy (ET) without progestin.
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Adverse effects and complications
Hysterectomy by any approach has a relatively high incidence of complications, such as haemorrhagia
requiring transfusion, wound healing sequelae, bowel, ureter and bladder complications, and
infections. Hysterectomy requires a lengthy postoperative recovery period with hospital stay and sick-
leave days. A recent large prospective hysterectomy study from Finland showed major complication
rates between 2.6%-4.3% and total complication rates between 11.7%-19.2%, with no significant
differences between hysterectomy approaches (Brummer et al. 2011).
Previous follow-up studies have shown somewhat higher complication rates (Dicker et al. 1982,
Meltomaa et al. 1999). Hysterectomy is irreversible and causes permanent infertility. Hysterectomy
also  appears  to  have  some  adverse  long-term  effects.  Ovarian  function  seems  to  be  impaired  after
hysterectomy due to altered vascularity and may cause early menopause (Halmesmäki et al. 2004,
2007a, Farquhar and Steiner 2005). Most studies have, however, shown no negative impact on sexual
functioning (Thakar et al. 2002, Kuppermann et al. 2005, Halmesmäki et al. 2007b). An increased risk
for development of stress urinary incontinence and pelvic organ prolapse after hysterectomy has been
reported in many clinical trials (Altman et al. 2007, Lukanovic and Drazic 2010, Cooper et al. 2011).
Figure 2. Hysterectomies for benign reasons and for bleeding problems in Finland between
1998 and 2010.
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2.2.3 Other treatments
Other treatment modalities available for management of essential menorrhagia are oral medical
therapy and endometrial resection/ablation (EA). The mechanism, effectiveness and potential
unwanted outcomes of menorrhagia treatments are given in Table 1.
Medical treatments
Anti-fibrinolytic drugs, such as tranexamic acid, inhibit fibrinolysis and reduce MBL by about 40–
50% (Lethaby et al. 2000a). They are taken only during menstruation and are usually well tolerated.
Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the production of prostaglandins and
leukotrienes and reduce blood loss by 33–55% and also relieve menstrual cramps (Lethaby et al.
2007). NSAIDs need to be taken only during menstruation.
Progestins suppress endometrial growth and activity. Given as a 12-day course, from day 15 to day 26
of the menstrual cycle, oral progestins reduce MBL by 12-20%. Given as a 21-day course, from day 5
to day 26, MBL is reduced up to 87% (Lethaby et al. 2008). Oral progestins are considered
unacceptable for long-term use due to high prevalence of hormonal side effects (Irvine et al. 1998).
Injected depot progestines leads to amennorhea or oligomenorrhea, but irregular bleeding and spotting
are common and osteoporosis is a harmful side effect (Marjoribanks et al. 2006).
Combined oral contraceptives (COCs) stop ovarian function, inhibit endometrial growth and
development and reduce MBL by up to 50% and relieve cramping (Fraser and McCarron 1991).
However,  a  novel  COC,  estradiol  valerate/dienogest,  seems  to  reduce  MBL by  60-88% (Fraser  and
McCarron 2011, Jensen 2011).
Gonadotrophin-releasing hormone analogues (GnRH-as) block the hypothalamic-pituitary axis,
decrease gonadotropin levels and reduce gonadal hormone levels to the prepubertal range. The
endometrium is almost unexposed to hormone effects that result in amenorrhea. GnRH-as are
generally used only for short-term treatment due to the prevalence and severity of side effects such as
menopause-like symptoms and osteoporosis (NICE 2007).
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Endometrial ablation
In uterus-sparing treatments, the endometrium and underlying basal glands are the target of
destruction by various means. In second-generation techniques, which are performed without
hysteroscopy and almost exclusively used today, a probe producing microwaves or a deflated balloon
filled with heated fluid is moved into the uterus through the vagina and cervix. Compared with
hysterectomy, EA has a shorter operation time and hospital stay, quicker recovery and fewer
postoperative complications (Dickersin et al. 2008, Munro et al. 2011). However, the effects of EA,
hysterectomy and LNG-IUS on QoL are comparable (Marjoribanks et al. 2006, Blumenthal et al.
2011, Matteson et al. 2012). As the endometrium has a marked regeneration capacity, women are
likely to continue to experience some degree of menstrual bleeding, and there is no guarantee that
bleeding will be reduced to acceptable levels over time (Marjoribanks et al. 2006, Blumenthal et al.
2011, Matteson et al. 2012). Women treated by EA may need re-treatment if menorrhagia persists
(Lethaby et al. 2000b, Clegg et al. 2007, Munro et al. 2011).
2.3 Cost-effectiveness of menorrhagia treatments
Alternative treatment options for menorrhagia (surgical and medical) have raised important questions
about health outcomes, cost-effectiveness and allocation of resources (NICE 2007, Middleton et al.
2010, Bhattacharya et al. 2011, Blumenthal et al. 2011). Hysterectomy has been a preferred treatment
option for menorrhagia due to its definitive nature and high satisfaction rates (Matteson et al. 2012).
However, the associated complications and substantial costs cannot be ignored (Fernandez et al. 2003,
Halmesmäki et al. 2004, 2007a, Hurskainen et al. 2004b, Matteson et al. 2012). Less invasive
alternatives to hysterectomy, such as LNG-IUS and EA, have been increasingly used.
Effectiveness of interventions
Evaluation of the effectiveness of medical interventions, has traditionally been based on measures of
morbidity and mortality. Morbidity is based on changes in symptoms and clinical tests. HRQoL has
become an accepted and widely used outcome in clinical research trials, also in menorrhagia,
reflecting a patient’s experiences and preferences (Drummond and Jefferson 1996). The term HRQoL
includes physical, psychological and social functioning and perception of health status, pain and
overall satisfaction with life (Sanders et al. 1998). Measures are normally categorized as generic or
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disease-specific. Generic scales allow comparison between different clinical conditions in terms of
their impact on HRQoL. Single-value instruments, like EQ-5D (European Quality of Life-5
Dimensions; Euro Qol Group), generate one value for the overall HRQoL by using a weighting of the
population’s reference values and can be used in economic evaluation and to calculate of quality-
adjusted life-years (QALYs). Those like RAND 36 (RAND 36-Item Health Survey Questionnaire) and
Nottingham Health Profile (NHP) produce a HRQoL profile with several dimensions allowing a
detailed assessment of several aspects of HRQoL. In addition, two condition-specific outcome
measures have been developed for women with menorrhagia, including the Menorrhagia Outcomes
Questionnaire (Lamping et al. 1998) and the Multi-attribute Questionnaire (Clark et al. 2002). These
measures are rarely used, but they are useful in conjunction with to generic measures because they
give a more accurate picture of menorrhagia-related symptoms.
The most commonly used outcomes reflecting the effectiveness of menorrhagia treatments are
reduction of MBL and increase in blood haemoglobin concentration. However, MBL values or
haemoglobin concentration do not reflect the subjective suffering, as menorrhagia has a strong effect
on womens QoL, including both physical and psychological health (Coulter et al. 1994). Also social
and working abilities may be disrupted, and women seek help for their menstrual problems mostly
because of the deleterious effect on their QoL. In the evaluation of the menorrhagia treatment, RAND
36 is the most commonly used validated HRQoL measurement (Clark et al. 2002). HRQoL measures
are well suited for comparison of treatments for research purposes, but if they are used for individual
patients’ problems emerge with other health and associated confounding factors. Patient satisfaction is
widely used as a primary effectiveness outcome measure in studies of treatment for menorrhagia
(Crow et al. 2002).
Health economics
Cost-effectiveness analysis is a form of economic analysis that compares the relative costs and
outcomes of two or more courses of action. Typically, cost-effectiveness analysis is expressed in terms
of  a  ratio  where  the  denominator  is  a  gain  in  health  from  a  measure  and  the  numerator  is  the  cost
associated with the health gain. A special case of cost-effectiveness is cost-utility analysis, where the
effects are measured in terms of QALYs. Cost-effectiveness is typically expressed as an incremental
cost per additional QALY gained.
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Cost-effectiveness of hysterectomy in the treatment of menorrhagia
The amount and costs of an additional QALY gained by hysterectomy have been calculated in a
Finnish prospective trial (Taipale et al. 2009). The amount of QALYs gained until menopause was
0.183 in menorrhagia patients and the cost of additional QALY gained by hysterectomy among was
€19415. However, the cost of QALY gained by hysterectomy has been lower in modelling trials and
has varied between trials, as the results depends on the method of HRQoL measurement, follow-up
time and unit costs of treatments (Table 2).
Costs and effectiveness of LNG-IUS and hysterectomy compared with endometrial
ablation
When comparing EA and LNG-IUS in the treatment of menorrhagia, both are effective in reducing
MBL and equal in patient satisfaction and HRQoL during 5 years (Marjoribanks et al. 2006, Tam et al.
2006, Kaunitz et al. 2009, Middleton et al. 2010, de Souza et al. 2010, Bhattacharya et al. 2011).
Studies have concentrated on short- and medium-term outcomes after hysterectomy and EA, but long-
term controlled comparisons of hysterectomy with EA in women with menorrhagia are few
(Middleton et al. 2010, Roberts et al. 2011, Bhattacharya et al. 2011, Munro et al. 2011, Matteson et
al.  2012).  In  a  recent  meta-analysis,  second-generation  EA  was  found  to  be  less  costly  but  also
provided fewer QALYs than hysterectomy, making hysterectomy the most cost-effective strategy
overall (Bhattacharya et al. 2011, Roberts et al. 2011). However, a recent systematic review reported
no difference in HRQoL or patient satisfaction between hysterectomy and EA, although hysterectomy
had significant better bleeding and pain control (Matteson et al. 2012).
Cost-effectiveness of LNG-IUS compared with Hysterectomy
Overview of previous trials suggests that hysterectomy is successful in the treatment of menorrhagia
and that LNG-IUS is the most effective of the medical treatments. However, comparative studies of
LNG-IUS and hysterectomy are few (Table 2). The first of the studies was the randomized
comparative trial from Finland (VuoKKo-study), which showed that LNG-IUS is more cost-effective
than hysterectomy after 1-year and 5-year follow-ups, with no difference in patient satisfaction or
HRQoL (Hurskainen et al. 2001b, 2004b). The overall costs at 12 months ($1530 vs. $4222) and 5
years ($2817 vs. $4460) were substantially lower in the LNG-IUS group than in the hysterectomy
group, although 42% of the women originally assigned to the LNG-IUS group eventually underwent
hysterectomy (Hurskainen et al. 2001b, 2004b).
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The majority of studies comparing LNG-IUS and hysterectomy are modelling studies analysed by
Markov model or meta-analyses (Table 2). Most of these studies have proposed the LNG-IUS as the
most cost-effective treatment option, and it is usually favoured as first-line treatment (Blumenthal et
al. 2006, Marjoribanks et al. 2006, Clegg et al. 2007, NICE 2007). An economic modelling study from
the UK undertaken for National Institute for Health and Clinical Excellence (NICE) guidelines on
menorrhagia, suggested that LNG-IUS generated more QALYs at a lower cost than any other medical
or surgical treatment considered (NICE 2007). However, a recent meta-analysis and modelling study
using individual patient data on clinical effectiveness and cost-effectiveness of the treatment of
menorrhagia found hysterectomy to be more cost-effective, albeit more expensive treatment compared
to  LNG-IUS  or  EA  (Bhattacharya  et  al.  2011,  Roberts  et  al.  2011).  The  paucity  of  RCTs  and  the
limitations of modelling studies can explain the contradictory findings of the trials. In addition, two
review articles of menorrhagia treatments have recently been published. The first article suggests
LNG-IUS as the most cost-effective treatment option (Blumenthal et al. 2011) and the second
concludes that hysterectomy is the most effective in reducing MBL but found no difference in HRQoL
(Matteson et al. 2012). Moreover, hysterectomy was associated with the highest risk for adverse
effects and complications, while less invasive treatment options, such as LNG-IUS, carry a significant
risk for re-treatment or surgery (Matteson et al. 2012).
Table 2. Summary of trials comparing LNG-IUS and hysterectomy in the treatment of menorrhagia.
Study Interventions Assessment tool Study design Prices based to Outcomes
Randomized controlled trials
Lähteenmäki et al. 1998 LNG-IUS HRQoL (VAS), Randomized VAS scores did not change from baseline to 6 months
(n=28) Proportion of Controlled in the control group, but significantly improved in each category
Continue women cancelling clinical trial over (general wellbeing, work performance, physical activity, sex
curren treatment their decision 1 year life and leisure activity) in the LNG-IUS group (p?0.002),
(n=28) to undergo and were maintained to 1 year.
until hysterectomy hysterectomy At 6 months, 64.3% of the women in the LNG-IUS group and
14.3% in the control group had cancelled their decision to undergo
hysterectomy (p<0.001). At 1 year, 57% of the women
in the LNG-IUS group had undergone  hysterectomy.
Hurskainen et al. 2001, 2004 LNG-IUS Cost-effectiveness, Randomised Finland 1996 Both LNG-IUS and hysterectomy were associated
(n=119) HRQoL, sexual function, controlled trial over  for firs year, with a 0.1 increase in HRQoL (EQ-5D)
Hysterectomy Depression, anxiety, 1 year and 2001 thereafter compared with baseline.
(n=117) MBL, S-Hb 5 years The total estimated cost (including productivity losses)
per woman over 1 year:
LNG-IUS=US $1530
Hysterectomy=US $4222
The total (including productivity losses) estimated
discounted cost per woman over 5 years:
LNG-IUS=US $2817
Hysterectomy=US $4660
LNG-IUS and hysterectomy improved haemoglobin levels
significantly and equally.
Ozdegimenci et al. 2011 LNG-IUS S-Hb, HRQoL Randomized LNG-IUS and hysterectomy improved haemoglobin levels
(Treatment of adenomyosis- (n=43) World Health Organization controlled cliinical significantly and equally.
related menorrhagia) Hysterectomy Quality of Life-Short Form, trial over 1 year Both treatments lead to improvements in HRQoL, but
(n=43) Turkish version LNG-IUS had superior effects on psychological and social life.
(WHOQOL-BREFTR)
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Modelling studies
You et al. 2006 LNG-IUS Cost-effectiveness Markov model over  Hong Kong Cost per QALY gained for base-case analysis:
Hysterectomy 5 years year of costs LNG-IUS = US $979
Endometrial destruction (Four hypothetical not specified Oral medical treatment=US $1204
Oral medical treatment cohorts designed to Endometrial ablation=US $1338
simulate health care Hysterectomy=US $1456
Resource utilization Incremental cost per QALY gained for treatment strategies
and QALYs) compared individually with the least costly option (LNG-IUS):
Oral medical treatment=Dominated by LNG-IUS
Endometrial ablation=Dominated by LNG-IUS
Hysterectomy=US $23500
Hysterectomy group was the most effective (4.725 QALYs).
Clegg et al. 2007 LNG-IUS followed by Cost-effectiveness Markov model over UK The expected 5-year costs of treating menorrhagia per patient:
endometrial ablation (L-A) 5 years 2004/2005 L-A=UK £828 with 4.14 QALY-expected gain
LNG-IUS followed by (Five hypothetical L-H=UK £1355 with 4.12 QALY-expected gain
hysterectomy (L-H) cohorts designed to TBEA=UK £1679 with 4.13 QALY-expected gain
Thermal balloon endo- simulate costs MEA=UK £1812 with 4.13 QALY-expected gain
metrial ablation (TBEA) QALYs associated Hysterectomy=UK £2983 with 4.01 QALY-expected gain
Microwawe endometrial with menorrhagia LNG-IUS treatment followed by ablation dominated
ablation (MEA) treatment) all of the alternative treatments.
Hysterectomy Hysterectomy was dominated by the alternative treatments.
National Institute of LNG-IUS Cost-effectiveness Markov model over UK Incremental cost per QALY gained at 5 years
Clinical Excellence 2007 Tranexamic acid 5 years 2004 compared with LNG-IUS as first-line treatment:
(NICE 2007) Mefenamic acid (Five hypothetical LNG-IUS (compared with no treatment)=£840
Combined oral cohorts designed to Tranexamic acid=Dominated by LNG-IUS
contraceptives simulate costs Mefenamic acid=Dominated by LNG-IUS
Surgery QALYs associated Combined oral contraceptives=Dominated by LNG-IUS
with menorrhagia Surgery=Dominated by LNG-IUS
treatment)
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Bhattacharya et al. 2011 LNG-IUS Cost-effectiveness Individual patient UK Rates of dissatisfaction:
(Middleton et al. 2010) Endometrial ablation (10-year follow-up) data meta-analysis 2008 LNG-IUS and second-generation EA were similar
(Roberts el al. 2011) (EA first generation) dissatisfaction of existing RCTs (18.1% vs. 22.5%, p=0.4)
EA (second generation) (1-year follow-up) Direct and indirect Indirect estimates suggested hysterectomy preferable to second-
Hysterectomy comparisons generation EA (5% vs 11% p=0.006), but suggest that hysterectomy
Individual patent data of Markov model is preferable to LNG-IUS was weak (5% vs 17%, p=0.07)
2814 women) (Four hypothetical Hysterectomy was the most cost-effective treatment.
cohorts of women It dominated first-generation EA and, although more expensive,
with menorrhagia) produced more QALYs than second-generation EA and LNG-IUS.
The incremental cost-effectiveness ratios for hysterectomy
compared with LNG-IUS was £1440 per additional QALY and
compared with second-generation EA was £970 per additional QALY.
Systematic reviews with meta-analyses
Marjoribanks et al. 2006 Surgery (hysterectomy HRQoL, improvement of Systematic review LNG-IUS provides a better alternative to surgery than oral medication
or endometrial ablation) menorrhagia, safety, and meta-analysis Compared with women with LNG-IUS:
Medical therapy acceptability (Cochrane Satisfaction, HRQoL and reduced, MBL are similar in women
(LNG-IUS or (from 1-year follow-up database) with endometrial destruction.
medical treatments) to-5 year follow-up) Satisfaction and HRQoL are similar, but the reduction in MBL is
12 parallel group RCTs greater in women with hysterectomy. Also serious complications and
a total of 1049 women higher costs are associated with hysterectomy.
LNG-IUS, levonorgestrel-releasing intrauterinen system. HRQoL, health-related quality of life. S-hb, serum haemoglobin. MBL, menstrual blood loss. QALY, quality-adjusted life-year.
EA, endometrial ablation.  VAS, visual analogue scale. RCT, randomised controlled trial.
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2.4 Lower abdominal pain and back pain in menorrhagia
Menorrhagia and dysmenorrohea are the most frequent gynaecological complaints of women of
reproductive age and often occur simultaneously (Yoo et al. 2011). Elevated prostaglandin synthesis
and inflammatory processes play an important role in both conditions and may produce intense uterine
contractions with associated vasoconstriction of the small vessels in the uterine wall (French 2005).
The painful contractions are often associated with lower abdominal pain and back pain.
Dysmenorrhoea, lower abdominal pain and back pain impair QoL, as does menorrhagia, and must be
treated. It is therefore important to determine whether menorrhagia treatment cures lower abdominal
pain  or  back  pain  at  the  same  time.  However,  sometimes  lower  abdominal  pain  and  back  pain  can
emerge as an adverse effect of menorrhagia treatment.
Effect of LNG-IUS
The beneficial effect of LNG-IUS on dysmenorrhoea and chronic pelvic pain has been demonstrated
in many clinical trials (Jensen et al. 2005, Varma et al. 2006, Anpalagan and Condous 2008,
Alhamdan et al. 2010). The mechanism of action of LNG-IUS in treating pelvic pain and
dysmenorrhoea is its local progestogenic effect, resulting in changes in a range of molecular
mechanisms, associated with excessive uterine contractions and troublesome cramps (Fraser 2010). In
addition, LNG-IUS reduces blood flow in the uterine artery and the subendometrial spiral arteries,
which can explain the reduction in primary dysmenorrhea (Anpalagan and Condous 2008). Moreover,
LNG-IUS has been shown to be an effective treatment for lower abdominal pain or back pain related
to endometriosis or adenomyosis (Maia et al. 2003, Bahamondes et al. 2007). On the other hand, some
studies have reported an increase in lower abdominal pain and back pain as an adverse effect of LNG-
IUS (Soysal et al. 2002, Lethaby et al. 2005, Kriplani et al. 2007).
Effect of hysterectomy
Hysterectomy is an effective treatment for dysmenorrhoea; most women with chronic pelvic pain
improve after the procedure (Learnman et al. 2004). However, in some women pain persists or
develops after surgery (5-32%) (Brandsborg et al. 2007, 2008). Pain may be caused by bowel spasm,
which hysterectomy does not treat. The mechanisms of chronic postoperative pain are poorly
understood, but nerve damage during surgery or a continuous inflammatory response, or both, may
lead to an altered pain perception (Brandsborg et al. 2008). Chronic pelvic pain may also be explained
by adhesions after hysterectomy. Moreover, increased back pain after hysterectomy is reported in
some studies (Carlson et al. 1994, Ceausu et al. 2006, Wijnhoven et al. 2006).
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2.5 Lower urinary tract symptoms
Lower urinary tract symptoms (LUTS), particularly urinary incontinence (UI) are major health
problems and have significant effects on women’s QoL (Miner 2004, Kenton and Mueller 2006,
Gimbel et al. 2007). Daily living, hygiene, emotional and psychological health and lifestyle are
changed because of incontinence (Imamura et al. 2010). UI of varying degree affects the lives of 20%
of middle-aged women and 40% of elderly women (Thomas et al. 1980, Mäkinen et al. 1992a,
Hunskaar et al. 2004, Milsom 2009). The new joint report of the International Urogynaecological
Association and the International Continence Society on the terminology of female pelvic floor
dysfunction from the year 2010 classified LUTS into six groups: urinary incontinence symptoms,
sensory symptoms, bladder storage symptoms, voiding and postmicturition symptoms, lower urinary
tract pain and lower urinary tract infection. The most common types of urinary problems are stress
urinary incontinence (SUI) (complaint of involuntary loss of urine on effort or physical exercise, or on
sneezing or coughing), urgency urinary incontinence (UUI) (complaint of involuntary loss of urine
associated with urgency) and mixed urinary incontinence (complaint of involuntary loss of urine
associated with urgency and also with effort or physical exertion or on sneezing or coughing) (Haylen
et al. 2010). The most prevalent type of incontinence is SUI in women under 55 years of age. At later
ages, mixed urinary incontinence becomes the most common type of incontinence (Hunskaar et al.
2004).
Effect of LNG-IUS
Only  one  trial  has  evaluated  the  effect  of  LNG-IUS  on  LUTS.  A  nationwide  cohort  study  from
Sweden compared incidence of UI symptoms among women using LNG-IUS, oral contraceptives or
no contraception (Iliadou et al. 2009). No difference was present between women with LNG-IUS and
those with no contraception, but oral contraception users had significantly reduced risk for UI. Women
with oral contraception or no contraception were significantly younger and had had fewer pregnancies
than LNG-IUS users, but the results remained unchanged after adjustment. There is no evidence that
LNG-IUS has an effect on LUTS or urinary tract infections (UTIs). However, as LNG-IUS seems to
cause vaginal flora disturbance and may increase the rate of vulvovaginal infections (Haukkamaa et al.
1986,  Donders  et  al.  2011),  the  rate  of  UTIs  may  also  be  increased.  On  the  other  hand,  increased
vaginal discharge can prevent dryness of the vagina and may affect the occurrence of LUTS.
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Effect of hysterectomy
LUTS and lower urinary tract dysfunction have been reported to be more prevalent in women who
have undergone hysterectomy. Most of the studies have shown an increased risk for both UUI and SUI
after hysterectomy (Brown et al. 2000, van der Vaart et al. 2002, Altman et al. 2007). A 60% increase
in risk for UI is described, but only in women aged over 60 years, as the development of UI after
hysterectomy usually takes many years (Brown et al. 2000).
Development of LUTS could be explained by damage occurring during surgery to the innervation and
supportive tissues of the pelvis or by changes in urethral pressure dynamics due to distorted pelvic
organ anatomy (Prior et al. 1992, DeLancey 1997). As hysterectomy changes the anatomy and
function of pelvic organs it may also increase the risk of UTIs. However, long-term studies of the
effect of hysterectomy on UTIs are lacking. Some studies have evaluated the effects of different
surgical approaches. LUTS appear to be more common following vaginal hysterectomy than
abdominal hysterectomy (Lakeman et al. 2010, 2011). A possible explanation is that a
difference exists in damage of the pelvic innervation between the approaches. However, some
studies have reported an increased risk for UI after hysterectomy, irrespective of surgical
approach (Altman et al. 2007).
2.6 Cardiovascular disease risk factors
Cardiovascular disease (CVD) is the leading cause of death for women. Approximately 10 000 women
in Finland (www.stat.fi) and 8.6 million women worldwide (World Health Organization 2004) die of
CVDs annually. The potential differences in risk factors and clinical profile of CVD in women have
been extensively studied (Stramba-Badiale et al. 2006). Smoking, diabetes, hypertension, abdominal
obesity, metabolic syndrome and associated insulin resistance, increased levels of serum lipids and
inflammation are the main risk factors for CVD among women.
Inflammatory serum markers
The pathogenesis of atherosclerosis can be considered as inflammatory process in which inflammation
plays a fundamental role at all stages from inception and development to thrombotic complications
(Libby 2002, Lind 2003). Elevated levels of serum inflammatory markers among patients with CVDs,
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as well as apparently healthy women, have proven to predict future adverse vascular events and
deaths.  A  number  of  inflammatory  biomarkers  have  been  used  as  risk  indicators  of  CVDs.  Such
mediators include C-reactive protein (CRP), tumour necrosis factor ? (TNF-?), fibrinogen, various
adhesion molecules, selectins and cytokines (Libby 2002, Blankenberg et al. 2003, Lind 2003).
CRP is a classical acute-phase protein produced mainly by the liver in response to pro-inflammatory
cytokines. CRP is a mediator of immune responses against various pathogens and damaged cells of the
host (Casas et al. 2008). Modestly elevated baseline CRP levels have been associated with a long-term
risk of coronary heart disease in general populations, and use of CRP as part of a global coronary risk
assessment strategy in adults without known CVD has been suggested (Danesh et al. 2004). The
pathogenic and clinical significance of the association between CRP and CVD is controversial (Casas
et al. 2004). The term “high-sensitivity” CRP (hsCRP) is used to refer to measurement of CRP using
immunoassay methods with sufficient sensitivity to quantify CRP throughout its normal range (in
contrast to acute-phase responses).
TNF-? is produced by several types of cells, especially by macrophages. Most organs of the body
appear to be affected by TNF-? and it has a variety of functions, including growth-stimulating
properties and growth-inhibitory processes, beneficial immune responses and a role in local immune
responses (Locksley et al. 2001). TNF-? is involved in the pathogenesis of atherosclerosis by
impairing endothelial function. In addition, TNF-? has been shown to impair insulin signalling
(Kleinbongard et al. 2011). Increased plasma TNF-? can predict risk of CVD (Libby 2002).
Effect of LNG-IUS
The effects of LNG-IUS on serum lipids and lipoproteins have been studied in women of reproductive
age (Nilsson et al. 1981b, Morin-Papunen et al. 2008) and in women with menorrhagia (Kayikcioglu
et  al.  2006).  An  association  between  use  of  LNG-IUS  and  reduced  levels  of  both  total  and  HDL
cholesterol, yet an unaltered HDL/total cholesterol ratio, has been demonstrated among fertile-aged
women (Morin-Papunen et al. 2008). However, two other studies found no effect on serum lipid levels
(Nilsson et al. 1981b, Kayikcioglu et al. 2006). The use of LNG-IUS was not associated with changes
in blood pressure or elevated levels of serum CRP (Morin-Papunen et al. 2008), but an associaton with
increased levels of serum glucose in women with menorrhagia was seen (Kayikcioglu et al. 2006).
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 Effect of hysterectomy
Hysterectomy may be accompanied by responses that predispose women to CVD (Luoto et al. 1995,
Howard et al. 2005). Hysterectomy impairs ovarian function and may cause early menopause
(Halmesmäki et al. 2004, 2007a, Farquhar and Steiner 2005). Early menopause, in turn, may induce
low-grade inflammation in the body and increase the risk for CVD (Abu-Taha et al. 2009). A recent
population-based cohort study from Sweden revealed that hysterectomy in women aged 50 years or
younger substantially increases the risk for CVD later in life, and oopherectomy further adds to the
risk of both coronary heart disease and stroke (Ingelsson et al. 2011). Some studies have shown an
association between hysterectomy and high blood pressure (Luoto et al. 1995, Kharazmi et al. 2007),
and ufavorable lipid profile (Zhang et al. 2005).
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3. Objectives of the study
The main objective of this thesis was to compare LNG-IUS and hysterectomy in the treatment of
menorrhagia in the long term to obtain new knowledge for clinical decision-making and patient
counselling as well as in implementing primary or special health care. More specifically, the aim was
to assess the cost-effectiveness and other health effects of these two treatment modalities, as
menorrhagia is a very common problem, requiring treatment.
Specific objectives were to compare the effect of LNG-IUS and hysterectomy on:
1     quality of life and cost-effectiveness (Study I)
2     lower abdominal pain and back pain (Study II)
3     lower urinary tract symptoms (Study III)
4     cardiovascular disease risk factors (Study IV)
in the treatment of menorrhagia.
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4. Patients and methods
4.1 Study protocol and study population
A total of 598 women referred for menorrhagia to the five University Hospitals in Finland between
November 1994 and November 1997 were assessed by a study gynaecologist, and 184 (31%) of the
women were excluded because of predefined exclusion criteria (Figure 3) (Hurskainen et al. 2001b).
During the first visit all eligible women were informed of the different treatment modalities for
menorrhagia and the purpose of the trial. By the second visit, 178 (43%) of these women decided not
to participate for the following reasons: treatment preference (hysterectomy n=71, LNG-IUS or some
other medical treatment n=37, EA n=3), refusal of any treatment (n=28), still planning pregnancy
(n=11), did not want randomization (n=5), or other reason (n=23) (Figure 3). The women excluded or
not participating did not differ from the study group in terms of sociodemographic factors, age,
employment status or occupation. All 236 women included were aged 35-49 years (mean 43.1 and
median 43.0 years), were menstruating, had completed their family size and were eligible for
hysterectomy and LNG-IUS.
Hysterectomy was performed abdominally, vaginally or laparoscopically by (or supervised by) an
experienced gynecologist. The mean waiting time for the operation was 6.7 months (range 12 days to
21 months). The LNG-IUS (Mirena®, Bayer Oy, Turku, Finland) was inserted during the
randomization visit on cycle day one to seven.
Randomization was performed separately for each centre in randomly varying clusters using
numbered, opaque, sealed envelopes. Of the 236 women, 107 were randomized in Helsinki, 44 in
Kuopio, 22 in Oulu, 21 in Tampere and 42 in Turku. The follow-ups took place 6 and 12 months after
the treatment and again 5 and 10 years after the randomization. The trial profile is shown in Figure 3.
A questionnaire was completed by the gynecologist during each follow-up visit and another by the
participant at home before randomization and before each follow-up visit.
This study is a continuation of the 1- and 5-year follow-ups and is based on the same study protocol
and study population (Hurskainen et al. 2001b, Hurskainen et al. 2004b).
The trial has been registered in clinicaltrials.gov with the identifier NCT00966264.
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Figure 3. The trial profile.
598 women screened
236 randomized
362 excluded
119 assigned to LNG-IUS 117 assigned to hysterectomy
106 analysed at 6 months
112 analysed at 12 months
117 analysed at 6 months
116 analysed at 12 months
11 lost to 6-month follow-up
? 11 withdrew
2 lost to 6-month follow-up
? 2 withdrew
3 lost to 12-month follow-up
? 3 withdrew
5 lost to 12-month follow-up
? 5 withdrew
117 analysed at 5 years 115 analysed at 5 years
2 lost to 5-year follow-up
? 2 withdrew
2 lost to 5-year follow-up
? 1 withdrew, 1 died
110 analysed at 10 years 111 analysed at 10 years
9 lost to 10-year follow-up
? 8 withdrew, 1 died
6 lost to 10-year follow-up
? 4 withdrew, 2 died
84 submucous fibroids
14 endometrial polyps
4 ovarian tumours
3 cervical pathology
20 bowel/urinary symptoms due to fibroids
25 lack of indication for hysterectomy
3 history of malignancies
7 menopause
3 severe depression
7 metrorrhagia as main complaint
10 previous treatment failure with LNG-IUS
3 severe acne
1 uterine malformation
11 treatment preference
28 refused any treatment
11 still planning pregnancy
5 did not want randomization
23 other reason not to participate
Studies
I-IV
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Ethics
All participants gave their written informed consent. The study protocol was approved by the Ethics
Committees of all university hospitals and STAKES (National Research and Development Centre for
Welfare and Health) in Finland. Ethics reference no. 249/E8/04; date of approval: 26 august 2004
(ethics approval granted by the Institutional Review Board of the Helsinki University Hospital).
4.2 Outcomes
The questionnaire of participants contained information on body mass index (BMI), smoking, parity,
age at menarche, deliveries, marital status, level of education, employment, smoking, chronic diseases,
regular use of medication, physical and hormonal symptoms, HRQoL instruments, instruments of
psychosocial well-being, health care use, sick-leave days and travel costs. Gynaecologists completed a
form that included information on abortions, gynaecological infections, menstrual cycle, duration of
menorrhagia, contraception, operations and treatments for menorrhagia as well as findings of physical
examination. In addition, the questionnaire contained information about LNG-IUS-associated bleeding
problems, reasons for discontinuation and details and complications of surgery. Data on all performed
hysterectomies and use of LNG-IUS were confirmed from medical records and the Hospital Discharge
Registry of the Finnish National Institute for Health and Welfare.
4.2.1 Health-related quality of life and other psychosocial well-being
HRQoL and other measures of psychosocial well-being were measured at baseline and at each follow-
up visit by questionnaires containing HRQoL instruments. The 5-Dimensional EuroQol (EQ-5D) was
selected as the primary measure of effectiveness because it provides a single numeric score for
HRQoL, is universally used and has been validated in the Finnish general population. The EQ-5D
includes five 3-level dimensions: morbidity, self-care, usual activities, pain, and mood. The score
index, ranging from 0 to 1, was calculated from relative weights for the dimensions obtained from a
Finnish population survey. The validated Finnish version of the RAND 36-Item Short-Form Health
Survey (RAND-36) was also used to measure HRQoL. The RAND-36 includes eight multi-item
dimensions: general health, physical functioning, mental health, social functioning, vitality, pain and
physical and emotional role functioning. Each subscale ranges from 0 to 100, higher scores indicating
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better HRQoL. The reference values of healthy and chronically ill women were obtained from two
large population surveys (Ohinmaa and Sintonen 1996, Aalto et al. 1999). The general health
assessment was recorded using an EQ-5D visual analogue scale (EQ-5D VAS), ranging from 0 to 100.
Anxiety was measured by the validated Finnish version of the Spielberger State-Trait Anxiety
Inventory (STAI), ranging from 20 to 80 (Spielberger et al. 1970). Depression was measured using the
13-item version of Beck’s Depression Inventory (BDI; scale 0-39) (Beck et al. 1974). Sexually related
factors were assessed by the McCoy Sex Scale (MSS) as modified by Wiklund (McCoy and Davidson
1985, Wiklund et al. 1993). The MSS comprises three subscales: sexual satisfaction (5 items, subscale
5-35), sexual problems (2 items, subscale range 2-14) and satisfaction with partner (3 items, subscale
3-21). On the scales, more anxiety, more depression, more sexual satisfaction, more sexual problems
and more satisfaction with partner are indicated by higher scores.
4.2.2 Costs and cost-effectiveness
Data on direct costs, including use of hospital services (operations, inpatient days, other procedures,
outpatient visits), and on indirect costs, including sick-leave days as productivity losses, were obtained
from medical records and questionnaires. Information on other visits to doctors for menorrhagia,
Papanicolaou tests and out-of-pocket costs (medication and travelling) related to menorrhagia were
obtained from questionnaires. The costs of hospital services were obtained from the 10-year period,
whereas the costs of health care out of hospital, out-of-pocket costs, and indirect costs (sick-leave
days) were obtained from first and fifth study years (Hurskainen et al. 2004b) and again from the
period during 5-10 years.
A pricing system based on diagnostic related groups used by Helsinki University Hospital was used
for pricing the hospital procedures. The first year costs were based on 1996 price levels, the costs over
1-5 years on 2001 price levels and the costs over 5-10 years on 2006 price levels. The currency
conversion had its basis in purchasing power parities in 1996 (US $1 = FIM 5.89) (Organization for
Economic Co-operation and Development 1993) and in 2002 when Finland implemented the euro
(FIM 1 = EUR  €0.168). The unit cost of hysterectomy included one preoperative visit, the actual
operation, and 1-5 inpatient days ($1864 in 1996, $2055 in 2001, $3187 in 2006). If a longer stay in
hospital was needed, additional days were priced according to the average bed day price ($247 in
1996, $297 in 2001, $363 in 2006). The cost of primary health-service care was calculated from the
unit costs of these services in the City of Helsinki Occupational Health Care Centres. The productivity
loss per sick-leave day was defined as the average daily gross wage of women in Finland, including
social security ($71 in 1996, $85 in 2001, $142 in 2006). The costs were discounted by the commonly
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recommended rate of 3% per year (Drummond and Jefferson 1996) to the 1996 level (average year for
treatment decisions).
Uncertainty was assessed in the model parameters by sensitivity analysis. We tested results based on
higher discount rate (5%, which is another commonly used discount rate) (Drummond and Jefferson
1996), lower estimate of productivity loss (one-third of average wage rate) (Koopmanschap and
Rutten 1994), and different prices of hysterectomy due to different pricing systems applied in other
countries. Furthermore, the results were tested using la ower hysterectomy rate (n = 25, 21%) in the
LNG-IUS group.
The additional QALYs gained by the treatments were calculated by using 12-month, 5-year and 10-
year values of EQ-5D, assuming that HRQoL would have remained at a baseline level without
treatment. The incremental cost per additional QALY gained was calculated for both treatments using
the number of QALYs gained and the total cost of menorrhagia treatment per participant.
4.2.3 Lower abdominal pain and back pain
Lower abdominal pain and back pain were recorded at baseline and at each follow-up visit using
Likert-scale questions on frequency of lower abdominal pain and back pain during the last six months
in Study II. The scores ranged from 1 to 4 (1 indicating never or rarely, 2 indicating monthly, 3
indicating weekly and 4 indicating nearly every day). The intensity of pain during the last six months
was recorded by a visual analogue scale, range from 1 to 7 (1 indicating no pain and 7 indicating the
worst possible pain). To evaluate the change in pain after treatment, we determined the pain score by
multiplying the frequency of pain by the intensity of pain (range from 1 to 28). The scores were
compared between 6 months and baseline, 12 months and 6 months, 5 years and 12 months, 5 years
and baseline, 10 years and 5 years and 10 years and baseline.
4.2.4 Lower urinary tract symptoms
Lower urinary tract symptoms (LUTS), including stress urinary incontinence (SUI), urge urinary
incontinence (UUI), increased daytime frequency (IDF), dysuria and feeling of incomplete emptying
(FIE) (yes/no) were enquired about for the previous six months, at baseline and at each follow-up visit.
SUI was defined as involuntary leakage on effort or exertion, UUI as involuntary leakage
accompanied by or immediately preceded by urgency, IDF as patients opinion that she voided too
often by day, dysuria as burning during urination and FIE as the feeling experienced by the individual
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after passing urine (Blaivas et al. 1997, Abrams et al. 2003). To assess the severity of UI and the
impact of UI on every day life, the Urinary Incontinence Severity Score questionnaire (UISS) was
used. The UISS questionnaire has been designed by the Finnish Gynaecological Society’s
urogynaecologic working group (Mäkinen et al. 1992b, Stach-Lempinen et al. 2001), and it consist of
10 questions with a three-point scoring system (0 = not at all, 1 = sometimes, 2 = often). On a scale
ranging from 0 to 20 (0-100%), the higher scores indicate severe symptoms. The number of UTIs was
questioned at baseline and each follow-up visit. The questionnaire completed by gynaecologists
included information on surgical procedures for UI as well as on microbiologically confirmed UTIs.
Surgery for UI was also confirmed from medical records. The records for the use of medication for UI
were obtained from the Registry of Purchased Drugs of the Finnish Social Insurance Institution, which
keeps a registry of of all purchased prescription-only medicines.
4.2.5 Cardiovascular disease risk factors
At the 10-year follow-up visit, blood pressure, waist circumference and the serum concentrations of
total cholesterol, high- and low-density lipoprotein cholesterol and triglycerides were measured. The
weight was self-reported and the BMI was calculated. The levels of serum hsCRP and TNF-? were
determined at baseline, 5 years and 10 years (the methods described below). Data on the use of
medication for the treatment of diabetes, hypertension, ischaemic heart disease and
hypercholesterolaemia as well as ET use were obtained from the Social Insurance Institution of
Finland.
4.2.6 Laboratory investigations
Menstrual blood loss (MBL) was measured before randomization and before each follow-up visit
using the alkaline haematin method (Hurskainen et al. 1998). At 10 years, none of the women
provided MBL samples.
Blood haemoglobin concentrations were measured using a Coulter Counter T660 (Coulter Electronics
Ltd., London, England). The blood samples were taken during menstrual days 1-7 at baseline and at
follow-up visits.
Serum concentrations of total cholesterol, HDL-cholesterol and triglycerides were measured using
enzymatic colorimetric test using Roche Diagnostics Cholesterol CHOD-PAP method, HDL-C plus 3rd
generation method, and Triglycerides GPO-PAP method (Hitachi Modular PP-analyzer, Hitachi Ltd.,
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Tokyo). Serum concentration of LDL-cholesterol was calculated according to the Friedewald
equation.
Serum TNF-? concentration was determined by commercial ELISA kits (Duoset, Genzyme
Diagnostics, Cambridge, USA) according to the manufacturer’s instructions. The lower detection limit
was 10 pg/ml.
Serum CRP levels were quantifed using an immunofluorometric CRP kit (Innotrac Diag, Turku,
Finland). The sensitivity of the assay is 0.05 mg/l, with an assay range of 0.05-50 mg/l. As CRP values
>10 ?g/ml may be more consistent with acute inflammation, the data were also analysed after
excluding these high values (baseline n=4, 5 years n=11, 10 years n=11).
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4.3 Analysis
4.3.1 Study groups
In Studies I and II, all analyses were performed by intention-to-treat principle. In Study II, the data
were analysed also by actual treatment, and in studies III and IV all analyses were performed by actual
treatment, as 55 (46%) of the women randomized to LNG-IUS had had a hysterectomy during the 10-
year follow-up (Figure 4). The actual treatment groups at 5 years consisted of 159 women who had
had a hysterectomy (hysterectomy group) and 77 women without a hysterectomy (LNG-IUS group)
(58 of these 77 women had LNG-IUS in situ still at 5 years). Correspondingly, the actual treatment
group at 10 years consisted of 164 women who had had a hysterectomy and of 71 women without a
hysterectomy (45 of these 71 women had LNG-IUS in situ still at 10 years). Data of treatment
modality at 10 years were missing for one woman. The baseline characteristics were tested separately
for original study groups and for actual treatment groups (Table 3.)
Table 3. Baseline characteristics of the study population at baseline and at 10 years.
Intention-to-treat Actual treatment at 10 years
LNG-IUS
(n = 119)
Hysterectomy
(n = 117)
LNG-IUS
(n = 71)
Hysterectomy
(n = 164)
Women in LNG-IUS group
with hysterectomy (n = 55)
All other women
(n = 181)
Age (years) 43.1 43.1 43.3 42.7 42.9 43.1
(SD 3.5) (SD 3.2) (SD 3.6) (SD 3.1)  (SD 3.3) (SD 3.4)
BMI (kg/m²) 26.6* 25.1* 25.7 26.3 26.6 25.7
 (SD 5.1) (SD 4.5) (SD 4.8) (SD 5.2) (SD 4.9) (SD 4.8)
Parity 2.1 2.0 2.0 2.1 2.1 2.1
(SD 1.0)  (SD 1.2) (SD 1.0) (SD 1.2) (SD 1.1) (SD 1.1)
Smoker 38 (32%) 27 (23%) 22 (31%) 43 (26%) 16 (29%) 49 (27%)
Menstrual blood loss (ml) 130 128 129 129 125 130
(SD 116) (SD 116)  (SD 116) (SD 109) (SD 115) (SD 117)
Education
  Elementary 39 (32%) 33 (28%) 24 (34%) 48 (28%) 18 (32%) 54 (30%)
  Lower secondary 52 (44%) 47 (40%) 29 (41%) 69 (41%) 23 (42%) 76 (42%)
  Upper secondary 28 (24%) 37 (32%) 18 (25%) 47 (30%) 14 (25%) 51(28%)
Unemployed 10 (8%) 8 (7%) 9 (13%)** 8 (5%) 1 (2%) 17 (9%)
*p=0.02, ** p=0.03
Total number of women in actual treatment analysis is 235, as the data of treatment modality at 10 years were missing for one
woman. Actual treatment analyses compare women with hysterectomy with all other women
.
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4.3.2 Statistics
The data were analysed by SPSS 14.0, SPSS 15.0, SPSS 16.0 and SPSS 17.0 versions for Windows
and STATA 11.1. The target of 115 patients for each treatment group was set by power calculations
based on HRQoL measured by EQ-5D standard deviation (SD) of 19% (derived from a Finnish 34-49-
year-old female population (Ohinmaa and Sintonen 1998) and ?-level of 0.05 (Hurskainen et al.
2001b). The study had 80% power to detect a 7.5% difference between the groups. In Studies III and
IV, the power calculation was based on a sample size of 164 patients in the hysterectomy group and 71
patients in the LNG-IUS group, and an ?-level of 0.05. Study III had an 80% power to detect a 15%
difference in the incidence of LUTS. Study IV had an 80% power to detect a 15% difference in the
CVD risk factors.
Chi-square test or Fisher’s exact test was used to test the differences in the dichotomized variables
between the groups pre- and post-treatment. Student’s t-test for independent samples was used to
analyse the differences in continuous variables with normal distribution and Mann-Whitney U-test for
variables not following normal distribution. Changes within the group, before and after the treatment,
were tested by Student’s t-test for dependent samples when parameters followed normal distribution
and by Wilcoxon signed-rank test when parameters were not normally distributed.
Either multivariate logistic or linear regression model was used to test factors associated with change
in variables or contributing factors. In this analysis, the potential contributing factors were added
either in continuous or in dichotomized form. In addition, all confounding factors were tested one by
one in a univariate regression model. In Study IV Pearson’s correlation was used to evaluate the
correlation between the levels of hsCRP and TNF-?.
To assess the total change trajectories of HRQoL and psychosocial outcomes over the 10-year follow-
up period, we applied random-intercept multilevel longitudinal modelling by pooling all four
measurement times (baseline and 1-year, 5-year and 10-year follow-ups) in a single analysis. The
method does not require full data for all measurement times, so all participants and their available
person-observations of the four measurement times were included in this analysis.
Odds ratios  were calculated to approximate the relative risk (RR) with 95% confidence intervals.  P-
values <0.05 were considered significant.
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5. Results
5.1 Clinical characteristics and findings (Studies I – IV)
The mean age of the study population 10 years after the treatment was 53.1 years (median 53.0 years,
range 46–59 years, 77% of the women > 51 years of age), thus most women had reached menopause.
Selected baseline characteristics of the study population, including the intention-to-treat population,
the actual treatment population and the 55 women who were originally randomized to treatment by
LNG-IUS but eventually underwent hysterectomy, are shown in Table 3. The groups were comparable
except that BMI (intention-to-treat) and unemployment (actual treatment) were slightly higher in the
LNG-IUS group.
The 10-year continuation rate was 94% (Figure 3).
5.1.1 LNG-IUS arm
After 10 years, 55 (46%) of the 119 women randomized to treatment by LNG-IUS had had a
hysterectomy, 44 (37%) had LNG-IUS in situ, 18 had no LNG-IUS or hysterectomy, one had died and
one woman had missing data (Figure 4). Of the hysterectomies, 13 (24%) were performed vaginally,
10 (18%) abdominally, and 32 (58%) laparoscopically. Eight women had bilateral salpingo-
oophorectomy with hysterectomy. Intraoperative or postoperative complications occurred in 15 (27%)
of the 55 women who had had a hysterectomy; these included postoperative pelvic infection (n=9,
16%), strong abdominal pain (n=3, 5%), wound infection (n=2, 4%), heavy perioperative bleeding
(n=1, 2%), ileus (n=1, 2%), postoperative bleeding (n=1, 2%), postoperative fever (n=1, 2%), and
urinary retention (n=1, 2%). No major complications (pulmonary embolism, re-operation or visceral
damage; bladder, bowel or ureter injury) occurred. Reasons for LNG-IUS removals and
hysterectomies during the first 5 years were intermenstrual bleeding (n=42), heavy bleeding (n=19),
hormonal symptoms (n=18), abdominal pain (n=6), depression (n=2), recurrent thromboembolic
disease (n=1) and benign ovarian cyst (n=1). Some of the women reported more than one reason, and
one woman wanted hysterectomy without any specific indication. The reasons for removal of LNG-
IUS after 5 years were menopause (n=8) and breast cancer (n=3). All five women who had had a
hysterectomy after 5 years had fibroids with bleeding problems as the main indication. Three of these
women also reported pressure symptoms.
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At 12 months, 41 (51%) of the 81 women with LNG-IUS in situ reported amenorrhoea or
oligomenorrhoea and 26 (32%) reported irregular or intermenstrual bleeding. Correspondingly at 5
years, 43 (75%) oft he 57 women with LNG-IUS reported amenorrhoea or oligomenorrhoea and 11
(19%) reported irregular or intermenstrual bleeding. At 10 years, 40 (91%) of the 44 women with
LNG-IUS in situ reported amennorhoea or oligomenorrhoea, one (2%) reported irregular or
intermenstrual bleeding and none reported heavy menstrual bleeding.
5.1.2 Hysterectomy arm
Of the 117 women randomized to hysterectomy, 109 (93%) had had a hysterectomy, eight had no
hysterectomy and one of them had LNG-IUS in situ after 10 years (Figure 4). Of the 109
hysterectomies, 30 (28%) were performed vaginally, 22 (20%) abdominally and 57 (52%)
laparoscopically. All hysterectomies were performed between baseline and 5 years. Intraoperative or
postoperative complications, including wound infection (n=12, 11%), infected pelvic haematoma
(n=6, 5%), urinary retention (n=4, 4%), severe abdominal pain (n=3, 3%), ileus (n=2, 2%),
postoperative bleeding (n=2, 2%), postoperative fever (n=2, 2%), wound rupture (n=2, 2%), peritonitis
(n=1, 1%), ureter lesion (n=1, 1%) and vesicovaginal fistula (n=1, 1%), occurred in 37 (34%) women.
Major complications occurred in three women (3%). During the 10-year follow-up eight women had
bilateral salpingo-oophorectomy. Seven of the eight women with no hysterectomy reported
amenorrhea or oligomenorrhea. One had LNG-IUS in situ. One woman reported normal menstrual
bleeding.
5.1.3 Laboratory results
At baseline, the mean MBL was 130ml (SD 116) in the LNG-IUS group and 128ml (SD 116) in the
hysterectomy group (Table 3). At 12 months, the mean MBL among LNG-IUS users was 13ml (SD
23.5, range 1-92). Only four women at 5 years (mean MBL 17 ml, SD 11.3, range 8-32 ml) and none
of he women at 10 years contributed their MBL samples. There was significant increase in blood
haemoglobin concentration in both study groups, with no significant differences between the groups
(Figure 5).
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Figure 5. Mean (g/l) blood haemoglobin concentration in the LNG-IUS group
        and the hysterectomy group over a the 10-year period.
No significant differences were present between the study groups.
5.2 Health related quality of life and psychosocial well-being
outcomes (Study I)
The baseline EQ-5D scores of subjects in HRQoL were significantly lower than the mean scores of
same-aged Finnish women (Ohinmaa and Sintonen 1996). The RAND-36 scores were also
significantly lower in women with menorrhagia than in healthy Finnish women of the same age,
corresponding to the score of women with chronic illness (Aalto et al. 1999).
HRQoL (by EQ-5D and RAND-36) and psychosocial well-being improved significantly during the
first 5 years (Figures 6 and 7). The improvement was most striking during the first year, reaching the
best HRQoL values 12 months after the treatment. After the 12-month follow-up, HRQoL decreased
gradually. Nevertheless, 5 years after the treatment, HRQoL and other psychosocial measures were
still significantly better than baseline, with no significant difference between the study groups
(Hurskainen et al. 2004b). During the period 5-10 years most of the measures of HRQoL and
psychosocial well-being decreased significantly.
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Between baseline and 10 years, EQ-5D scores remained at baseline level, with no difference between
the groups. Of the dimensions measured by the RAND-36, emotional well-being and social
functioning improved in the LNG-IUS group (p=0.01) and energy increased in both groups (LNG-IUS
p=0.01, hysterectomy p=0.03). General health assessed by VAS was impaired in both groups (p=0.01,
p<0.001). Of other psychosocial well-being markers, sexual satisfaction (p=0.01, p=0.01) and
satisfaction with partner (p<0.001, p=0.01) decreased and sexual problems increased (p<0.001,
p=0.02) in both groups. In addition, anxiety decreased in the LNG-IUS group (p<0.001). No
significant differences were found between the groups over periods of baseline-10 years or 5-10 years.
The multilevel models suggested fairly steep initial improvement of HRQoL within the first year after
baseline, but then less steeply declining levels during the rest of the follow-up period (Figures 6 and
7). Despite this decline, the average levels of HRQoL tended to be higher after 10 years than at
baseline, albeit not significantly. There were no significant differences in trajectories of HRQoL and
psychosocial outcomes between LNG-IUS and hysterectomy groups over 10 years.
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Figure 6. HRQoL trajectories in hysterectomy and LNG-IUS goups.
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95% confidence intervals are shown only for hysterectomy group for reasons of clarity.
The differences between the groups is not significant if the confidence interval exceeds the average of the LNG-IUS group.
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5.3 Costs and cost-utility outcomes (Study I)
The discounted total cost of treatment of menorrhagia per participant over 10 years was $3423 in the
LNG-IUS group and $4937 in the hysterectomy group (direct cost $2291 vs. $3036, indirect cost $1133
vs. $1900) (Table 5). Both the discounted direct cost and the discounted indirect cost were significantly
lower in the LNG-IUS group than in the hysterectomy group. The discounted total costs per participant
between 5 and 10 years were $606 in the LNG-IUS group and $277 in the hysterectomy group. Only the
costs related to menorrhagia treatment were included in the analysis (Table 4).
The total cost per participant using a higher or lower discount rate, higher or lower hysterectomy cost, or
lower estimate of productivity loss (sensitivity analysis) was again lower in the LNG-IUS group than in
the hysterectomy group (Table 5). The total cost per participant in the LNG-IUS group with a lower
hysterectomy rate (n =30) and a higher LNG-IUS continuation rate (n = 67) was $308 lower than the base
case (Table 5).
LNG-IUS produced 0.45 QALYs and the incremental cost per additional QALY gained was $7607.
Hysterectomy, by contrast, resulted in 0.51 QALYs at a cost of $9680 per additional QALY.
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Table 4. Total costs of menorrhagia in the LNG-IUS and hysterectomy groups during the 10-year follow-up.
Unit Cost, US$ LNG-IUS Hysterectomy
Cost component 1996 2001 2006 n over 10 years Cost, US$ n over 10 years Cost, US$
Direct costs (5 to 10 years) (5 to 10 years)
  LNG-IUS     First 185 165 117 21675 2 331
  LNG-IUS     Re-inserted 185 165 216 84 (26) 15307 1 (1) 216
  Hysterectomy (includes 1-5 inpatient days) 1864 2055 3187 55 (5) 114102 109 203601
      Extra inpatient days 247 297 363 21 (1) 6058 45 11097
      Re-laparoscopy 1502 1569 1 1569
  Re-admissions due to complication
      Infection (inpatient days) 247 297 10 2668 35 8631
      Urinary retention (inpatient days) 247 297 3 740
      Occlusion (inpatient days) 247 297 12 3569 17 4886
      Secondary haemorrhagia (operation) 1527 2 3054
      Laparoscopy due to pain 1475 1 1475
      Suture of Ileum (with 11 days in intensive care) 1 11000
      Laparotomy due to occlusion 1 3102
      Nephrostoma (2 inpatient days) 1 1273
      Ureterneocystostomia and oophorectomy 1 5494
  Curattage/Hysteroscopy 542 798 823 8 (2) 5921
  Thermoablation 1225 1 1225
  Laparoscopic oophorectomy for ovarian cyst 1475 1503 5 7429 3 4508
  Abdominal salpingo-oophorectomy for ovarian cyst 3187 1 (1) 3187
  Outpatient visits (controls* and complications) 110 124 253  775 (123) 105621  713 (113) 96729
  Health care use out of hospital
     Visits to general practitioner at health centre 46 58 82 62 (33) 4186 18 (10) 1186
     Visits to private physican 27 40 54 10 (8) 486 9 (8) 459
     Visits to private gynaecologist 42 53 112 46 (16) 3355 22 (8) 1625
     Papanicolaou test 31 20  263 (180) 6137  185 (146) 4112
     Medication  (Out-of-pocket costs) 1033 3265
     Travel  (Out-of-pocket costs) 552 986
Indirect costs
  Sick-leave days 71 85 142  1718 (234) 148975  3080 (30) 224719
Summary of health care costs
Direct costs
    Total health care costs 300893 370657
    Discounted total health care costs per participant** 2291 3036
Indirect costs
    Discounted productivity losses per participant** 1133 1900
Total costs 449868 595376
    Total costs per participant 3780 5089
Discounted total costs** 407355 577573
Discounted total costs per participant** 3423 4937
*Controls indicate planned follow-up visits at 6 months, 1 year, 5 years and 10 years. For women having hysterectomy, there
was also a planned visit 4 weeks after hysterectomy, **Discounted by 3%.
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Table 5. Sensitivity analysis.
Total cost per participant, US $
Variable used in analysis LNG-IUS Hysterectomy
Base case* 3423 4937
Discount rates for costs
      No discounting 3780 5089
      Discount rate 5% 3247 4862
Productivity loss (indirect cost)
      Lower estimate** 2668 3669
Cost of hysterectomy
      Lower estimate*** 3324 4590
      Mean hysterectomy cost in the US in 1996**** 3861 6917
      Laparoscopic hysterectomy cost in the US in 2007 ***** 4876 8663
Number of hysterectomies in the LNG-IUS group
 n = 30****** 3115 4937
*Discounted by 3%, **One-third of the average wage rate, ***20% lower than base case.
****Mean cost of hysterectomy in the US in 1996 was $3995 (Dorsey et al. 1996).
*****Approximate cost of laparoscopic hysterectomy in the US in 2007 ($6973) (Sarlos et al. 2011).
******Without cost of 25 hysterectomies between 12 months and 5 years,
and with cost of 25 added LNG-IUS at 5 years and 25 added LNG-IUS at 10 years.
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5.4 Lower abdominal pain and back pain (Study II)
Lower abdominal pain
Lower abdominal pain was common before the treatment. At baseline, 45% of the women in the LNG-
IUS group (8% nearly every day, 15% weekly and 21% monthly) and 38% of the women in the
hysterectomy group (5% nearly every day, 9% weekly and 22% monthly) reported lower abdominal
pain. Lower abdominal pain decreased in both study groups during the 10 years after the treatment
(p<0.001), but the decline was most evident during the first 6 months (p<0.001) (Figure 8). After the
first year, more women in the LNG-IUS group (30%) than in the hysterectomy group (14%) suffered
from lower abdominal pain (p=0.02). Between baseline and 10 years, monthly abdominal pain
decreased most (LNG-IUS: from 21% to 7%, p<0.001, hysterectomy: from 22% to 8%, p<0.001), but
also the daily and weekly pain decreased significantly in the both study groups. At 10 years, 38% of
the women in the LNG-IUS group and 35% of the women in the hysterectomy group experienced less
often abdominal pain than before treatment. However 5% and 10% of the women, respectively, had
lower abdominal pain more often than before treatment.
Lower abdominal pain score (which combined occurrence and intensity of pain) showed no significant
differences between the study groups at baseline (Figure 10). No significant changes were noted
between baseline and 6 months, but between 6 and 12 months lower abdominal pain score decreased
in both groups (p=0.05 and p=0.02), with no significant difference between the groups. Overall,
between baseline and 10 years, lower abdominal pain score decreased in the LNG-IUS group (mean
-3.8, p=0.005) and in the hysterectomy group (mean -2.7, p=0.01), with no significant difference
between the groups. At 10 years, 70% of the women in LNG-IUS group and 73% of the women in
hysterectomy group experienced lower pain scores than at baseline, and correspondingly, 12% and
20% of the women had higher pain scores.
The multivariate model adjusted by age, BMI, ET and unemployment showed an association between
LNG-IUS use and a decrease in lower abdominal pain score between baseline and 10 years (p=0.04).
The route of hysterectomy (vaginal, abdominal or laparoscopic) did not explain the changes in pain
after hysterectomy.
The actual treatment analysis showed only minor differences relative to the intention-to-treat analysis.
Lower abdominal pain score decreased more among LNG-IUS users than among women with
hysterectomy between 6 months and 5 years. All of the other results were in line with the intention-to-
treat analysis.
53
Back pain
Before the treatment, back pain was common; 64% of the women in the LNG-IUS group (21% nearly
every day, 10% weekly, 33% monthly) and 65% of the women in the hysterectomy group (11% nearly
every day, 13% weekly, 41% monthly) reported back pain (Figure 9). After the treatment, occurrence
of back pain decreased in the both groups. At 10 years, 40% of the women in the LNG-IUS group and
42% of the women in the hysterectomy group reported back pain. The decrease in back pain was most
striking during the first 6 months, but still after 10 years the occurrence of back pain was significantly
lower than at baseline in both study groups (p<0.001), with no significant difference between the
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Figure 8. Occurrence of lower abdominal pain in the LNG-IUS group (a) and hysterectomy group (b)
during the 10- year follow-up. *Difference between the groups (p=0.02).
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groups. Monthly pain decreased most in both groups (LNG-IUS: from 33% to 17%, p<0.001 and
hysterectomy: 41% to 10%, p<0.001). Daily back pain decreased in the LNG-IUS group (from 21% to
14%, p=0.01) and increased in the hysterectomy group (from 11% to 25%, p<0.001). At 10 years,
29% of the women in the LNG-IUS group and 19% of the women in the hysterectomy group
experienced back pain less often and 13% and 25% of the women, respectively, experienced back pain
more often.
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Figure 9. Occurrence of back pain in the LNG-IUS group (a) and in the hysterectomy group (b)
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Before the treatment, back pain score was higher in the LNG-IUS group (mean 10.18) than in the
hysterectomy group (mean 8.44) (p=0.02) (Figure 10). Between baseline and 10 years, back pain score
decreased in the LNG-IUS group (mean -1.2, p=0.2) and increased in the hysterectomy group (mean
+1.8, p=0.06), with a significant difference emerging between the study groups (p=0.02). At 10 years,
52% of the women in LNG-IUS group and 33% of the women in hysterectomy group experienced
lower pain scores than at baseline. The corresponding proportions of women with higher pain scores
were 34% and 56%.
The multivariate model adjusted by age, BMI, ET and unemployment showed an association between
LNG-IUS use and a decrease in back pain score between baseline and 10 years (p=0.02). The route of
hysterectomy did not explain the changes in back pain.
The results by actual treatment were in line with intention-to-treat analyses.
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5.5 Lower urinary tract symptoms (Study III)
The baseline incidences of LUTS categorized by 10-year actual treatment group are given in Table 6.
No significant differences were present between the groups. None of the women had undergone
surgery for urinary incontinence (UI) before treatment. During the 10-year follow-up, three of the
hysterectomized women and one LNG-IUS user underwent a tension-free vaginal tape procedure. Re-
operation by the transobturator vaginal tape procedure was performed on one woman with
hysterectomy. None of the women had used medication for UI before treatment. During the10 years
women with hysterectomy used significantly more anticholinergics and duloxetine for UI than LNG-
IUS users (Table 7).
Table 6. Baseline incidence of urinary tract symptoms categorized by actual treatment.
Hysterectomy (n = 164) LNG-IUS (n = 71)
n (%) n (%)
Urinary tract infection (UTI)* 14 (9%) 5 (7%)
Urge urinary incontinence (UUI) 32 (20%) 8 (11%)
Stress urinary incontinence (SUI) 65 (40%) 29 (41%)
Dysuria 13 (8%) 5 (7%)
Increased daytime frequency (IDF) 51 (31%) 20 (28%)
Feeling of incomplete emptying (FIE) 26 (16%) 7 (10%)
* Self-reported.
No significant differences between the study groups.
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Table 7. Use of medication for urinary incontinence in the 10 years after hysterectomy or
treatment with LNG-IUS.
Hysterectomy LNG-IUS Difference between the groups
Anticholinergic
medicines Duloxetine Total
Anticholinergic
medicines Duloxetine Total OR (95% CI) p-value
n (%) n (%) n (%) n (%) n (%) n (%)
Baseline to
5 years 8 (5%) 0 8 (5%) 1 (1%) 0 1 (1%)
3.95
(0.49-32.14) 0.28
5 years to
10 years 10 (6%) 6 (4%)
16
(10%) 0 0 0 0.004
Baseline
to 10 years 14 (8%) 6 (4%)
20
(12%) 1 (1%) 0 1 (1%)
9.45
(1.24-71.87) 0.006
Analysed by actual treatment.
During the follow-up LUTS increased more among women with hysterectomy. Between baseline and
12 months, IDF decreased in the hysterectomy group (p<0.001) and SUI decreased in the LNG-IUS
group (p=0.006) (Table 8). Between 12 months and 10 years, UUI, SUI, dysuria and IDF increased
among women treated by hysterectomy (p<0.001, p=0.002, p=0.02, p=0.002) and IDF increased in the
LNG-IUS group (p=0.007). At 10 years, SUI was more common in hysterectomized women than in
treated with LNG-IUS (p=0.04). Correspondingly, FIE was more common among women with
hysterectomy at 5 years (p=0.04). At 10 years, the mean UISS score in the LNG-IUS group was 3.2
(16%) (SD 2.8) and in the hysterectomy group 4.0 (20%) (SD 3.8) (p=0.09).
Between 5 and 10 years, lower urinary tract infections (UTIs) were more common in women with
hysterectomy than in women with LNG-IUS (Figure 9); 34% and 14 %, respectively, reported at least
one UTI (p=0.002). The corresponding proportions for microbiologically confirmed UTIs were 20%
and 9% (p=0.02).
The multivariate model adjusted by bilateral oophorectomy, age, parity, BMI, ET use and smoking
showed an association between UTIs and hysterectomy between 5 and 10 years (p=0.004) and
between FIE and hysterectomy at 5 years (p=0.03).
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Table 8. Incidence of urinary symptoms at baseline and at each follow-up after hysterectomy or
LNG-IUS insertion.
LNG-IUS Hysterectomy Difference between the groups
Lower urinary tract symptoms
n Total % n Total %  Odds ratio 95% CI p-value
Urge urinary incontinence
  Randomization 20 119 17  20 117 17 1.03 0.52-2.04 0.93
  6 months 12 105 11  9 114 8 0.66 0.27-1.65 0.38
  12 months 7 94 7  9 127 7 0.95 0.34-2.64 0.92
  5 years 9 72 13  20 153 13 1.05 0.45-2.44 0.91
  10 years 11 68 16  34 153 22 1.48 0.70-3.13 0.30
Stress urinary incontinenc
  Randomization 52 119 44  42 117 36 0.73 0.43-1.24 0.24
  6 months 32 105 30  37 114 32 1.10 0.62-1.94 0.75
  12 months 25 94 27  39 127 31 1.22 0.68-2.21 0.51
  5 years 24 72 33  58 153 38 1.22 0.68-2.20 0.51
  10 years 23 68 34  74 153 48 1.83 1.01-3.32 0.04
Dysuria
  Randomization 10 119 8  8 117 7 0.81 0.31-2.12 0.67
  6 months 10 105 10  8 114 7 0.72 0.27-1.89 0.50
  12 months 7 94 7  5 127 4 0.51 0.16-1.66 0.26
  5 years 3 72 4  14 153 9 2.32 0.64-8.33 0.19
  10 years 4 68 6  16 153 10 1.87 0.60-5.81 0.28
Increased daytime frequency
  Randomization 30 119 25  41 117 35 1.62 0.92-2.85 0.09
  6 months 23 105 22  24 114 21 0.95 0.50-1.81 0.88
  12 months 13 94 14  20 127 16 1.17 0.55-2.48 0.69
  5 years 13 72 18  43 153 28 1.77 0.88-3.56 0.11
  10 years 18 68 26  51 153 33 1.39 0.74-2.62 0.31
Feeling of incomplete emptying
  Randomization 20 115 17  13 117 11 0.63 0.30-1.32 0.22
  6 months 10 105 10  19 114 17 1.90 0.84-4.30 0.12
  12 months 8 94 9  18 127 14 1.78 0.74-4.28 0.20
  5 years 4 72 6  23 153 15 3.00 1.00-9.05 0.04
  10 years 6 68 9 29 153 19 2.42 0.95-6.13 0.06
Analysed by actual treatment.
Total number of observations is lower than the number of study participants, as some women did not answer all of the
questions.
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Figure 10. Proportion of women with at least one urinary tract infection after treatment with LNG-
IUS or hysterectomy.
UI, urinary tract infection.
Analysed by actual treatment.
Women with bilateral oophorectomies excluded.
Difference between groups: * p=0.002, ** p=0.02.
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5.6 Cardiovascular disease risk factors (Study IV)
At baseline, no differences existed in the use of medications for diabetes, hypertension, ischaemic
heart disease and hypercholesterolaemia between the study groups (Table 9). Between baseline and 10
years, medication for hypertension and hypercholesterolaemia increased in both groups (p<0.001),
with no difference between the groups, but use of diabetes medication increased only in women with
hysterectomy (p=0.008) (from 1.7% to 6.7%) (Table 11).
The traditional CVD risk factors (total cholesterol, high- and low-density cholesterol, blood pressure
and waist circumference) were analysed at 10 years; no significant differences emerged between the
groups. BMI increased significantly in both groups (LNG-IUS: +1.8kg/m2, hysterectomy: +2.2kg/m2,
p< 0.001), with no difference between the groups.
Table 9. Use of medication for hypertension, diabetes, hypercholesterolaemia and ischaemic heart
disease.
LNG-IUS Hysterectomy Change between the groups
n (%) n (%) p-value
Hypertension
Baseline 22 (18.9%)  15 (12.6%) 0.21
5 years 28 (37.8%)  48 (30.2%) 0.25
10 years 30 (42.2%)  71 (43.2%) 0.95
Diabetes
Baseline 6 (5.1%) 2 (1.7%) 0.17
5 years 6 (7.9%) 4 (2.5%) 0.05
10 years 6 (8.4%) 11 (6.7%) 0.57
Hypercholesterolemia
Baseline 1 (0.9%) 0 (0%) 0.31
5 years 5 (6.8%) 11 (6.9%) 0.96
10 years 15 (21.1%)  26 (15.8%) 0.27
Ischemic heart disease
Baseline 0 (0%) 1 (0.8%) 0.32
5 years 0 (0%) 2 (1.3%) 0.33
10 years 1 (1.4%) 4 (2.4%) 0.64
Number of women in treatment groups
Baseline 119 117
5 years 77 159
10 years 71 164
Analysed by actual treatment. Use of medication derived from the Social Insurance Institution of Finland.
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Oestrogen therapy (ET) was used by 8 women (10%) in the LNG-IUS group and by 52 women (33%)
in the hysterectomy group at 5 years (p< 0.001). At 10 years, ET was used by 19 women (27%) in the
LNG-IUS group and by 97 women (59%) in the hysterectomy group (p< 0.001). When the 16 women
with bilateral oophorectomy were excluded, the correspondingly numbers were 8 (10%) vs. 42 (29%)
at 5 years (p=0.003) and 19 (27%) vs. 83 (56%) at 10 years (p<0.001) (Figure 11).
Figure 11. Proportion of women using oestrogen therapy after treatment with LNG-IUS or
hysterectomy.
Analysed by actual treatment.
Women with bilateral oophorectomies (n=16) excluded.
Difference between the groups: * p=0.003, ** p<0.001.
0,00
10,00
20,00
30,00
40,00
50,00
60,00
baseline 6 months 12 months 5 years 10 years
LNG-IUS
Hysterectomy
%
 o
f w
om
en
 **
 **
 *
 *
62
Inflammatory serum markers
No significant differences between study groups were noted in the levels of hsCRP and TNF-? at
baseline. The levels of hsCRP did not change during the first 5 years (Figure 12). At 10 years, hsCRP
levels were higher among women with hysterectomy than among LNG-IUS users (p=0.04). At 5
years, women with hysterectomy had higher levels of TNF-? than women with LNG-IUS (p=0.001).
In both groups, TNF-? levels decreased after 5 years (Figure 10). Multivariate analysis (with potential
explaining factors of age, ET use, BMI, smoking, social status and oophorectomy) showed an
association between hysterectomy and levels of TNF-? at 5 years (p=0.003), whereas hsCRP was
associated with age (p=0.04) and BMI (p<0.001).
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Figure 12. Serum levels (median) of hsCRP (?g/ml) and TNF-? (pg/ml) at baseline and at 5 and 10
years after treatment by LNG-IUS or hysterectomy.
Analysed by actual treatment. Differences between groups *p=0.04, **p=0.001.
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6. Discussion
6.1 Methodological considerations
This study is the only long-term randomized trial comparing LNG-IUS and hysterectomy in the
treatment of essential menorrhagia. Power analysis was based on the main outcome measure
(HRQoL), and all five university hospitals in Finland were included. A wide range of outcome
measures was used to determine the effect of LNG-IUS and hysterectomy on HRQoL, costs, pain,
LUTS and CVD risk factors. Most of the instruments used were validated and HRQoL was estimated
by exceptionally many instruments. The costs of the treatments included both health care and
productivity losses and were calculated with a number of variables.
The randomization was successful, with similar subject characteristics in both arms. The only
differences between the study groups at baseline were slightly higher BMI and back pain score in the
LNG-IUS group. The dropout rate even at the 10-year follow-up was low (6%), suggesting a high
commitment of both participating women and doctors and a good study protocol. Thanks to this,
compliance bias is presumably absent in this study. As the inclusion criteria followed general clinical
guidelines, selection bias was unlikely as well. Over half of the women referred for menorrhagia to the
university hospital were excluded from the study. They either declined to participate or failed to meet
the criteria of either of the two treatment modalities. Therefore it is assumed that the study population
represents women who are candidates for both treatment modalities and that results are generalized.
The duration of follow-up in this study was exceptionally long. The mean age of menopause in
Finland was 50 years in 1997 and 51 years in 2007 (Pakarinen et al. 2010). The mean age of the study
population 10 years after the treatment was 53.1 years, meaning that most women had reached
menopause and menorrhagia was no longer a problem. The 10-year follow-up thus covers the entire
treatment of menorrhagia.
The discontinuation and hysterectomy rates in the LNG-IUS arm are in line with previous studies
(Marjoribanks et al. 2006, Matteson et al. 2012). However, our data were collected from women
referred to university hospitals for menorrhagia and meeting the criteria for hysterectomy. Had the
LNG-IUS treatment been initiated already in primary health care, the number of hysterectomies in the
LNG-IUS arm would likely have been much smaller. Women who were prepared for hysterectomy
seemed to poorly tolerate the bleeding problems with the LNG-IUS during the first months.
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The total complication rate of hysterectomy in this study was relatively high (total complications 32%,
major complications 2%) compared with complication rates in Finland in general (total complications
11.7-19.2%, major complications 2.6-4.3%) (Brummer et al. 2011). However, only this study included
strong postoperative abdominal pain to the complications. The approach of hysterectomy in this study
(vaginal hysterectomy (VH) 26%, abdominal hysterectomy (AH) 20%, laparoscopic hysterectomy
(LH) 54%) differed from the normal distribution of approaches in Finland in 1996 (VH 18%, AH
58%, LH 24%) and in 2006 (VH 44%, AH 32%, LH 24%). The high rate of laparoscopic
hysterectomies can be explained by the indication of essential menorrhagia for hysterectomies, usually
without uterine prolapse or large fibroids.
The  hysterectomies  performed  in  the  LNG-IUS group  are  part  of  the  treatment  flow also  in  normal
clinical work. This is why intention-to-treat analyses reflect well the results of the decision to start
treatment of menorrhagia either with hysterectomy or LNG-IUS. However, to even better show the
effect of hysterectomy or LNG-IUS, analyses were conducted by actual treatment in Studies III and
IV. The strength of evidence in these studies may be lower as the power of randomization was
lowered. However, the baseline characteristics of the 55 women originally randomized to LNG-IUS
group and who subsequently had hysterectomy did not differ from those of the other women. Another
limitation in the Studies III and IV was that in the actual treatment analysis women who had had
hysterectomy were compared with all other women, although only 45 women still had LNG-IUS in
situ  at  10  years.  One  woman  was  excluded  from  the  actual  treatment  analysis  at  10  years  due  to
missing data about treatment modality. This inaccuracy in actual treatment groups can weaken the
strength of the results in actual treatment analysis.
The questionnaires were sent home by post, allowing the patients sufficient time to respond. Some of
the women did not respond to all of the questions. This would have introduced a systematic recall bias
had it not been but was avoided by randomization and sophisticated statistical methods in HRQoL
analyses. Overall, the response rate was high, also lowering the bias. Because the reliability of
questionnaires may not be the best possible, other data sources were also used. The records for use of
medication were obtained from the registry of purchased drugs of the Finnish Social Insurance
Institution, which keeps a registry of all purchased prescription-only medicines. Data on special
reimbursements of diseases were confirmed from the registry of special reimbursements of medicines
of the Finnish Social Insurance Institution. Data on all performed hysterectomies and use of LNG-IUS
as well as on complications and surgery for UI were confirmed from medical records and the Hospital
Discharge Registry of the Finnish National Institute for Health and Welfare. The registries in Finland
have proven to be reliable (Suoyrjö et al. 2007).
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Some limitations in the calculation of cost-utility exist. Firstly, the EQ-5D values were measured at
baseline and at 1 year, 5 years and 10 years, not annually. Secondly, the cost-utility calculation was
based on the baseline values of EQ-5D (not on values of reference group) because we had no
randomized study group without treatment and there was no difference in HRQoL between the LNG-
IUS and hysterectomy groups. Despite this uncertainty in the QALY calculations, cost-utility values of
both treatment modalities were convincing. If we had had a reference group, it is expected that the
amount of QALYs gained would have been increased and the cost of QALY gained would have been
decreased, as the HRQoL tends to decrease with age (Ohinmaa and Sintonen 1996, Aalto et al. 1999).
6.2 Cost-effectiveness of LNG-IUS and hysterectomy in the
treatment of menorrhagia
Hysterectomy reduced MBL and improved HRQoL, but was the most expensive treatment option and
was also associated with a several of complications. In most women, LNG-IUS was effective in
reducing MBL; however, in the 10-year follow-up 55 (46%) of the women randomized to LNG-IUS
had undergone hysterectomy. Bleeding problems were the most common reasons for hysterectomy or
discontinuation of LNG-IUS use.
Health related quality of life
Menorrhagia  has  deleterious  effect  on  the  QoL  of  many  women.  The  results  of  our  study  are  in
accordance with previous reports showing significant improvement in HRQoL, anxiety and depression
after treatment of menorrhagia (Marjoribanks et al. 2006, Middleton et al. 2010, Blumenthal et al.
2011). At baseline, EQ-5D and RAND-36 scores of the study population were significantly lower than
the mean scores of age-matched Finnish women, and similar to the scores of women with chronic
illness (Ohinmaa and Sintonen 1996, Aalto et al. 1999). HRQoL and other measures of psychosocial
well-being improved in both groups, with no significant differences between the study groups. The
multilevel model showed that study groups followed very similar trajectories, but the trajectories of
women in the LNG-IUS group moved slightly below the trajectories of women in the hysterectomy
group, which mostly resulting from small baseline differences combined with non-significant
differences in change between baseline and 12-month follow-up.
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The impact of the treatment of menorrhagia on HRQoL was strongest after one year, yet the 5-year
values were still significantly better than baseline values. Between 5 and 10 years, the HRQoL
decreased, presumably explained by the effect of ageing, not by the effect of the treatment of
menorrhagia. Only five women needed more treatment for bleeding problems after 5 years; all others
were satisfied with their menstruation. The majority of women had reached menopause, and 90% of
the women in the LNG-IUS group were in amennorhoea already at 5-year follow-up. The reference
values of HRQoL, obtained from two large Finnish population surveys, are known to decrease with
ageing (Ohinmaa and Sintonen 1996, Aalto et al. 1999). The finding of impaired in sexual functioning
during ageing is also in line with previous studies showing declining sexuality after menopause
(McCoy and Davidson 1985, Dennerstein et al. 2003).
Ten years after treatment, most of the HRQoL values were still above or at the same level as baseline,
in contrast to HRQoL reference values of same-aged, women decreasing with age (Ohinmaa and
Sintonen, Aalto et al 1999). This difference between our results and reference values appears to be
related to treatment of menorrhagia. However, the HRQoL values of the study population at 5 and 10
years were still lower than reference values, but the difference was smaller than at baseline (Ohinmaa
and Sinotnen 1996, Aalto et al. 1999). Because menopause and ageing have a marked influence on
HRQoL, the only way to clarify the real effect of menorrhagia treatments on HRQoL is a randomized
study group of menorrhagia patients without treatment. Such a study design is not, however, ethical.
Our results support the findings of previous studies that the maximum HRQoL benefits of
menorrhagia treatments are achieved during the first year and are generally maintained up to 5 years
(Blumenthal et al. 2011). However, no study of the impact of LNG-IUS on HRQoL has continued
beyond 5 years.
Cost-effectiveness
LNG-IUS has previously been shown to be cost-effective at 1-year and 5-year follow-ups (Hurskainen
et al. 2001b, 2004b). Now we have shown that LNG-IUS remains cost-effective after 10 years.
Although 46% of the women assigned to the LNG-IUS group eventually underwent hysterectomy, the
discounted direct and indirect costs in the LNG-IUS group remained substantially lower than in the
hysterectomy group 10 years  after  treatment.  The decision to start  the treatment  with LNG-IUS was
approximately 31% less expensive than treatment with hysterectomy. Most (91%) of the
hysterectomies in the LNG-IUS group were performed during the first 5 years and 44% during the first
year. Only five women had a hysterectomy between 5 and 10 years. Had the costs of all
gynaecological treatments (including oestrogen therapy and medication for urinary incontinence) been
included in to the analysis, the difference of costs between the study groups would probably have been
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even more pronounced. On the other hand, the cost-saving of sanitary products after treatment of
menorrhagia or amennorhoea can be substantial.
During the 10-year period, the incremental cost per additional QALY gained was significantly lower
than the commonly accepted threshold value of $50 000 both in the LNG-IUS group ($7607) and in
the hysterectomy group ($9680), demonstrating the cost-effectiveness of both treatment modalities for
menorrhagia (Birch and Gafni 2004). In a recent Finnish prospective trial investigating utility and
costs of hysterectomy with benign indications, the cost of an additional QALY gained by
hysterectomy among menorrhagia patients was higher (€19415=$19620) than in this study (Taipale et
al. 2009). However, the follow-up of the study was only six months and the HRQoL was assumed to
continue at 6-month level until menopause. Moreover, HRQoL was measured by the 15D HRQoL
questionnaire, which may show lower HRQoL effects than EQ-5D.
Our results are consistent with many modelling studies and reviews that suggest LNG-IUS to be the
most cost-effective treatment option for menorrhagia (Clegg et al. 2007, NICE 2007, Blumenthal et al.
2011, Matteson et al. 2012). A modelling study from UK undertaken to inform National Institute for
Health and Clinical Excellence guidelines on menorrhagia, showed that LNG-IUS generated more
QALYs at a lower cost than any other medical or surgical treatment (NICE 2007). The most recent
review concluded that hysterectomy is the most effective treatment in reducing MBL, but found no
difference in HRQoL (Matteson et al. 2012). Hysterectomy was associated with the highest risk for
adverse effects and complications, while less-invasive treatment options, such as LNG-IUS, carried
significant risk for re-treatment or surgery (Matteson et al. 2012). By contrast, a recent systematic
meta-analysis and modelling study using individual patient data of clinical effectiveness and cost-
effectiveness of the treatment of menorrhagia found hysterectomy to be the most cost-effective, albeit
the most expensive, treatment compared with EA or LNG-IUS (Bhattacharya et al. 2011, Roberts et al.
2011). The lack of RCTs comparing LNG-IUS and hysterectomy and the problems and limitations of
modelling studies can explain the different results of the trials.
The Finnish Current Care guideline of menorrhagia treatment (Current Care editorial office 2005,
updated 2009) conclude that the appropriate treatment of menorrhagia improves patients’ QoL, and
that medical treatment, including a LNG-IUS, should usually be tried before surgical treatment. The
National Institute for Health and Clinical Excellence guideline on menorrhagia is consistent with
Finnish Current Care guideline and suggests LNG-IUS to be more cost-effective than any other
medical or surgical treatment considered (NICE 2007).
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6.3 Effect of LNG-IUS and hysterectomy on lower abdominal pain
and back pain
Lower abdominal pain is often associated with menorrhagia (Yoo et al. 2011). This finding was also
made here; 42% of the women reported lower abdominal pain before treatment, 22% reporting pain
monthly, 12% weekly and 7% nearly every day. Monthly lower abdominal pain, presumably related to
the menstrual cycle, was present in one of five women at baseline; it nearly halved during the follow-
up, as did monthly back pain.
Both LNG-IUS and hysterectomy decreased pain among menorrhagic women. In both groups, the
main decrease in frequency of pain occurred during the first 6 months and was maintained for up to 10
years. At the12-month follow-up, lower abdominal pain was more common in the LNG-IUS group.
This finding is in line with pain measures by the RAND-36 instrument showing that women with
hysterectomy suffered less pain at 12-month follow-up (Hurskainen et al. 2001b), but no longer at the
five-year-follow up (Hurskainen et al. 2004b). The greatest decrease in pain shortly after initiation of
the treatment may be partly explained by women’s expectations since outcomes are influenced by
subjective experiences. On the other hand, the main decrease in the pain score (occurrence and
intensity of pain combined) occurred between 6 months and 5 years.
Some of the women in both groups experienced more lower abdominal pain and back pain after the
treatment than before the treatment. This finding is consistent with previous trials showing that in most
cases both LNG-IUS (Jensen et al. 2005, Varma et al. 2006, Anpalagan and Condous 2008, Alhamdan
et al. 2010) and hysterectomy (Learman et al. 2004) reduce pain, but in some women lower abdominal
pain and back pain increase after hysterectomy (Wijnhoven et al. 2006, Brandsborg et al. 2007, 2008)
or after insertion of LNG-IUS (Lethaby et al. 2005, Kriplani et al. 2007). According to a review
article, chronic pain is reported by 5–32% of women after hysterectomy (Brandsborg et al. 2008).
However, surgery did relieve pain in the majority of women, and pain as a new symptom was reported
in 1–14.9% of women and increased pain in 2.9–5% of women with pre-operative pelvic pain. Pre-
operative pain was associated with a higher risk of having pelvic pain at follow-up. The prevalence of
chronic pain was similar irrespective of the technique of hysterectomy, a finding supported by this
study. A Danish nationwide study reported that 15% of women hysterectomized for benign reasons
develop chronic pelvic pain after hysterectomy (Brandsborg et al. 2007). In a non-randomised
prospective study among women with menorrhagia, 38.3% reported back pain as a side effect after 3
months’ use of LNG-IUS. However 77.5% of the women reported relieved dysmenorrhea at 3 months,
and after 2 years’ use of LNG-IUS none of the women had dysmenorrhea (Kriplani et al. 2007). The
results of this study agree with previous findings showing a decrease in lower abdominal pain in 38-
70% and in back pain in 28-52% of women in the LNG-IUS group, and, correspondinglyly in 35-73%
69
and 19-33% of women in the hysterectomy group. The correspondingly fugures for an increase in
abdominal pain and back pain were 5-12% and 13-34% in women with LNG-IUS and 10-20% and 25-
56% in women with hysterectomy.
Women in both groups experienced more back pain than lower abdominal pain. Moreover, back pain
increased (not significantly) in both groups between 5 and 10 years. Presumably much of the back
problems were associated with other causes of back pain, such as menorrhagia, which become more
common with age. However, back pain, mostly daily back pain, increased more in the hysterectomy
group than in the LNG-IUS group. A possible explanation for the increased pain after hysterectomy
could be adhesions and bowel problems caused by hysterectomy. Moreover, the risk of failure of the
pelvic floor, leading to vaginal prolapse, increases after hysterectomy (Mant et al. 1997). These kinds
of changes in anatomy may cause lower abdominal pain, back pain and spastic pelvic symptoms after
hysterectomy. The increase in back pain may be partly explained by age-related changes in bones and
muscles, possibly associated with hormonal changes, as hysterectomy seems to have a more
deleterious effect on ovaries than does LNG-IUS (Halmesmäki et al. 2006).
Overall, in the long run, LNG-IUS seems to be as beneficial as hysterectomy for lower abdominal pain
and for back pain even more beneficial.
6.4 Effect of LNG-IUS and hysterectomy on lower urinary tract
symptoms
After the treatment, women treated with hysterectomy had more LUTS, including SUI, FIE and UTIs,
than women treated with LNG-IUS. Women with hysterectomy also used also more medication for UI
than LNG-IUS recipients. In both groups, the incidence of LUTS decreased during the first year and
increased thereafter being close to baseline levels at 10 years. The marked decrease during the first
year post-treatment may be explained by improved QoL and by women’s expectations (Hurskainen et
al. 2004b). The subsequent increase in symptoms may be explained by ageing, as age is a known risk
factor for LUTS, particularly UI (Brown et al. 2000). The prevalence of UI and pelvic floor
dysfunction increases after 60 years of age (Brown et al. 2000, Luber et al. 2001), and it is assumed
that LUTS are more pronounced in an older study population.
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The findings of the effect of hysterectomy on lower urinary tract function have been contradictory in
previous studies. The duration of follow-up likely plays an important role in the evaluation of
outcomes (Samuelsson et al. 2000, Neumann et al. 2004). A population–based cohort study showed
that hysterectomy increases SUI surgery, irrespective of surgical technique (Altman et al. 2007).
Another population-based study found an increased risk for urge urinary incontinence (UUI) after
hysterectomy (van der Vaart et al. 2002), and a review article concluded that hysterectomy increases
the likelihood of UI in the long term (Brown et al. 2000). On the other hand, a RCT comparing
hysterectomy and EA found no increased risk of UI after hysterectomy in a 2-year follow-up
(Bhattacharya et al. 1996). Thakar et al. (2002) concluded in their randomized trial that neither total
nor subtotal hysterectomy adversely affected pelvic organ function at 12 months. Findings of studies
with a longer follow-up (Brown et al. 2000, van der Vaart et al. 2002, Altman et al. 2007) are in line
with our results showing increases in LUTS after hysterectomy, whereas studies with a short follow-
up have been unable to demonstrate an increase in UI after hysterectomy (Bhattacharya et al. 1996,
Thakar et al. 2002, Neumann et al. 2007). The incidence of LUTS in hysterectomized women in our
study was somewhat lower than in the trial of Thakar et al (2002), which compared total abdominal
hysterectomy and subtotal abdominal hysterectomy.
Considering the increase in the use of medication for UI among hysterectomized women and some
more surgery for UI, it can be assumed that without medication these women would have been even
more symptomatic. Most of the medicines used for UI were anticholinergics. Thus, the finding of no
differences in UUI and UISS between the study groups may be biased as a result of medication, and it
can speculated that UUI in particular would have been more pronounced among women treated with
hysterectomy.
It is possible that women in the LNG-IUS group with more LUTS could have had more
hysterectomies than women without LUTS. We controlled for this by comparing the incidence of
LUTS at baseline between the AT groups. No differences were found indicating that the threshold for
hysterectomy was not lower among women with LUTS. Although 20% of the women with
hysterectomy and 11% of the women with LNG-IUS reported UUI at baseline, the difference was not
significant. Thus, the grouping did not explain the increased LUTS among hysterectomized women.
An interesting and unprecedented observation was the association between UTIs and hysterectomy in
long term. Women with hysterectomy had significantly more UTIs than LNG-IUS users at 10 years.
This finding was confirmed by the multivariate model, where treatment modality was the only
explaining factor for UTIs. Anatomical changes following hysterectomy may predispose women to
UTIs and pelvic floor dysfunction. Although the risk for post-surgical UTI after hysterectomy is well
known (Mäkinen et al. 2001, Cadkova et al. 2008), no long-term exist on hysterectomy and UTIs.
However, the association between UTIs and UI is established (Moore et al. 2008), and this study
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showed a link between UTIs and UUI, and between UTIs and FIE. Hence, the increased risk for UTIs
after hysterectomy may develop via increased UI and incomplete emptying. A potential explanation
for increased UTIs and SUI in women with hysterectomy may be impaired ovarian function and
earlier menopause causing mucosal atrophy in the vagina and urethra. It is also possible that the local
progestin effect of LNG-IUS in the mucosa of the bladder and urethra protects against UTIs in LNG-
IUS users. Thus, whether the difference in the incidence of LUTS between the treatment groups is due
to a predisposing effect of hysterectomy or a protective effect of LNG-IUS is unclear.
6.5 Effect of LNG-IUS and hysterectomy on CVD risk factors
Women treated with hysterectomy had higher levels of TNF-? and hsCRP than women treated with
LNG-IUS  at  5  and  10  years  after  treatment.  The  results  suggest  that  hysterectomy  may  be
accompanied by responses that predispose women to CVD, consistent with previous findings (Howard
et al. 2005, Ingelsson et al. 2011). An increased risk may result from an earlier menopause in women
with hysterectomy, which may induce low-grade inflammation in the body (Farquhar and Steiner
2005, Halmesmäki et al. 2007a, Abu-Taha et al. 2009).
Interestingly, but not surprisingly, ET was significantly more often used by women treated with
hysterectomy than by LNG-IUS users at 5 years (29% vs. 10%) and 10 years (56% vs. 27%) after
treatment. Women with bilateral oophorectomy were excluded from the analysis. This finding
strengthens the link between hysterectomy and earlier menopause. The effect of ET on the risk of
CVD varies with age at the time of initiation of treatment. ET has a protective effect in younger
women, but in older women it increases the risk (Manson et al. 2007, Rossouw et al. 2007). However,
as the women in our trial were relatively young (average age at end of study 53.1 years), the effect of
ET use on CVD risk may have been protective rather than predisposing. Previous data have
demonstrated increased levels of hsCRP, but not TNF-?, among women receiving either oestrogen
alone therapy (Kwok et al. 2009) or combination therapy with progestin (Eilertsen et al. 2008). This
could in part explain the observed higher levels of hsCRP in the hysterectomy group, although
multivariate regression analysis did not find an association between ET and hsCRP levels. In line with
previous studies, a higher concentration of hsCRP was associated with BMI (Bochud et al. 2009) and
age (Werner et al. 2000), but not with smoking or social status. The hsCRP concentrations in the
groups observed in this study are consistent with those reported for healthy women (Ridker et al. 2000,
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Woloshin and Schwartz 2005). The LNG-IUS was not associated with changes in serum hsCRP levels,
which is also in line with earlier findings (Kayikcioglu et al. 2006).
Use of diabetes medication increased during the follow-up period in the hysterectomy group. Although
the number of women was low and the results are unlikely to be clinically significant, this is an
interesting finding, as increased levels of hsCRP are known to predict type 2 diabetes in humans, and
TNF-? causes insulin resistance in animal models (Hotamisligil 1999, Bochud et al. 2009)). After
adjusting for confounding factors (classic CVD risk factors), TNF-? levels were fully explained by
treatment modality and not by BMI. The significant increase in of TNF-? level 5 years after
hysterectomy may therefore reflect a low-grade inflammatory status of the body after hysterectomy,
and therefore being one of the key factors mediating increased CVD risk after hysterectomy.
The number of women receiving medication for hypercholesterolaemia, hypertension or ischaemic
heart disease increased in both groups during the follow-up period, in accord with an age-related
increase in serum cholesterol and blood pressure (Amery et al. 1978). No difference was present
between the treatment groups in the use of medication for these conditions, which is consistent with
the lack of differences between the groups in the levels of serum cholesterol or blood pressure. The
finding of the neutral effects of LNG-IUS on blood pressure, cholesterol and hsCRP supports earlier
research (Nilsson et al. 1981, Kayikcioglu et al. 2006, Morin-Papunen et al. 2008), strengthening the
presumption that LNG-IUS does not have an adverse effect on cholesterol, unlike oral progestins
(Graff-Iversen and Tonstad 2002).
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7. Summary and conclusions
In conclusion, this study shows that treatment of menorrhagia with LNG-IUS or hysterectomy
improves HRQoL significantly and similarly. The results highlight the importance of menorrhagia
treatment. The cost of starting treatment of menorrhagia with LNG-IUS was 31% less than the cost of
starting with hysterectomy, establishing LNG-IUS as the more cost-effective treatment option.
However, both LNG-IUS and hysterectomy had a commendable cost-utility value when the cost of
gained QALYs was calculated. Both hysterectomy and LNG-IUS decreased lower abdominal pain,
which is often associated with menorrhagia, but LNG-IUS seemed to a have more beneficial effect on
back pain.  Compared with treatment  by LNG-IUS, hysterectomy increased the risk for  LUTS in the
long run. Women treated with hysterectomy were more exposed to incomplete bladder emptying and
UTIs. They were also more likely to develop SUI and to need more medication for UI. Women treated
with hysterectomy used more ET reflecting earlier menopause, than women with LNG-IUS or without
treatment. Hysterectomy seemed to correlate with increased levels of TNF-? and hsCRP relative to
LNG-IUS or no treatment, suggesting that women undergoing hysterectomy may have an increased
risk for future cardiovascular events.
Menorrhagia is one of the most common reasons for women seeking medical care, and treatment is
frequently needed. When making treatment decisions for menorrhagia, costs, effectiveness and
potential long-term risks and benefits of the treatments should be weighed. This study confirms that
LNG-IUS should be the first choice in the treatment of menorrhagia. LNG-IUS should be tried at an
early stage and before planning hysterectomy.
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8. Summary in Finnish
Tässä kymmenen vuoden seurantatutkimuksessa verrattiin hormonikierukan ja kohdunpoiston
kustannusvaikuttavuutta runsaiden kuukautisten hoidossa. Lisäksi tutkimuksessa arvioitiin
hoitomuotojen vaikutusta elämänlaatuun ja psykososiaaliseen hyvinvointiin, alavatsa- ja selkäkipuihin,
alempien virtsateiden oireisiin sekä sydän- ja verisuonisairauksien riskitekijöihin.
VuoKKo-tutkimus (Vuodot, Kierukka, Kohdunpoisto) aloitettiin kaikkien Suomen yliopistollisten
naistenklinikoiden ja Stakesin yhteistyönä vuonna 1994. Aineisto koostui 236:sta 35-49-vuotiaasta
naisesta, jotka oli lähetetty runsaiden kuukautisten vuoksi jatkotutkimuksiin. Naisista 119
satunnaistettiin hoidettavaksi hormonikierukalla ja 117 kohdunpoistolla. Seurantakäynnit
(satunnaistaminen, 6kk, 12kk, 5v ja 10v) sisälsivät kliinisen tutkimuksen sekä kyselylomakkeet.
Kymmenenvuotisseurantaan osallistui 94% naisista. Kymmenenvuotiskäynnillä 55:lle (46%)
hormonikierukkaryhmän naisista oli tehty kohdunpoisto ja 44 (37%) naisella oli edelleen
hormonikierukka. Yleisin syy kierukan poistoon ensimmäisen viiden vuoden aikana oli vuotohäiriöt ja
jälkimmäisen viiden vuoden aikana menopaussi. Kohdunpoistoryhmässä 109 (93%) naiselle oli tehty
kohdunpoisto.
Hoitomuotojen vaikutusta terveyteen liittyvään elämälaatuun ja psykososiaaliseen hyvinvointiin
tutkittiin useilla validoiduilla mittareilla. Sekä hormonikierukan että kohdunpoiston todettiin
parantavan merkittävästi terveyteen liittyvää elämänlaatua ja psykososiaalista hyvinvointia, eikä
hoitoryhmien välillä todettu merkittävää eroa. Suurin paraneminen elämänlaadussa tapahtui
ensimmäisen vuoden aikana hoidon jälkeen. Tämän jälkeen terveyteen liittyvä elämänlaatu väheni
samalla tavalla molemmissa hoitoryhmissä, oletettavasti ikääntymisestä johtuen.
Kokonaiskustannuksiltaan 10 vuoden hoito hormonikierukkaryhmässä ($3423) oli 31% edullisempi
kuin kohdunpoistoryhmässä ($4937).
Ennen hoitoa alavatsakipuja oli 45%:lla hormonikierukkaryhmän ja 38%:lla kohdunpoistoryhmän
naisista ja selkäkipuja yli puolella (64% vs. 65%). Molemmat hoitomuodot vähensivät kipuja
merkittävästi. Kymmenenvuotiskäynnillä alavatsakipua valitti enää 12% hormonikierukkaryhmän ja
15% kohdunopoistoryhmän naisista ja selkäkipua 40% / 42% naisista. Molemmissa ryhmissä kivut
vähenivät eniten ensimmäisen kuuden kuukauden aikana ja kuukausittain ilmenevä kipu väheni eniten.
Kun kivun voimakkuus yhdistettiin esiintymistiheyteen, alavatsakipu väheni molemmissa ryhmissä,
mutta selkäkipu vain hormonikierukkaryhmässä.
Hoitomuotojen vaikutusta alempien virtsateiden oireisiin sekä sydän- varisuonisairauksien
riskitekijöihin tutkittiin toteutuneeen hoitomuodon mukaan. Kohdunpoistolla hoidetuilla naisilla oli
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enemmän ponnistusvirtsankarkailua (48% vs. 34%, p=0.04) ja he käyttivät enemmän lääkkeitä (12%
vs. 1%, p=0.006)) virtsankarkailun hoitoon kuin hormonikierukalla hoidetut naiset. Heillä ilmeni myös
enemmän rakon tyhjenemisongelmia (19% vs. 9%, p=0.04) ja virtsatieinfektiot olivat yleisempiä (34%
vs. 14%, p=0.002) kuin kierukkaryhmässä.
Sekä verenpainetauti että hyperkolesterolemia lisääntyivät molemmissa hoitoryhmissä, mutta
diabeteslääkkeiden käyttö lisääntyi vain kohdunpoistoryhmässä. Painoindeksi nousi samankaltaisesti
hormonikierukalla (+1.8 kg/m2) ja kohdunpoistolla (+2.2 kg/m2) hoidetuilla naisilla. Lisäksi
havaittiin, että naiset joilta kohtu oli poistettu käyttivät merkitsevästi enemmän estrogeenihoitoa kuin
hormonikierukalla hoidetut naiset viisi vuotta (29% vs. 10%, p=0.003) ja kymmenen vuotta (56% vs.
27%, p<0.001) hoidon jälkeen. Kohdunpoistolla hoidetuilla naisilla todettiin seerumissa korkeammat
sydän- ja verisuonisairauksien riskiä kuvaavien tulehduksellisten merkkiaineiden pitoisuudet (TNF-?
ja hsCRP). Tulokset vahvistavat käsitystä, että kohdunpoisto heikentää munasarjojen toimintaa ja
saattaa tämän seurauksena lisätä sydän- ja verisuonisairauksien riskiä.
Lähes joka kolmas nainen kärsii runsaista kuukautisista elämänsä aikana. Moni naisista hakee apua ja
tarvitsee hoitoa vaivaansa. Runsaat kuukautiset aiheuttavat huomattavia kustannuksia sekä potilaalle,
että terveydenhuollolle. Jos hoito aloitetaan hormonikierukalla päästään yhtä vaikuttavaan
hoitotulokseen kuin ohjaamalla naiset suoraan kohdunpoistoon, mutta merkittävästi alemmilla
kustannuksilla. Jos hoito aloitetaan jo perusterveydenhuollossa, kustannussäästöt ovat oletettavasti
tutkimuksen osoittamia säästöjä suuremmat. Hormonikierukka on turvallinen ja kustannustehokas
vaihtoehto kohdunpoistolle runsaiden kuukautisten hoidossa.
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